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Ligand activation of peroxisome proliferator-activated receptor gamma (PPARγ) 
has been shown to inhibit proliferation and induce apoptosis in human tumor cell 
types; however the molecular mechanism underlying these effects has not been 




 exchanger 1 
(NHE1) gene expression as a mechanism involved in reactive oxygen species 
(ROS) mediated regulation of tumor cells’ response to apoptosis. Interestingly, 
generation of ROS and the induction of intracellular acidosis through the 
inhibition of NHE1 activity have also been recently shown to be a mechanism 
associated with PPARγ-induced toxicity. Hence, we asked if NHE1 could be a 
PPARγ regulated gene and if regulation of NHE1 gene expression could explain 
some of the effects of PPARγ on cell proliferation and cell arrest. In agreement 
with a possible regulation of NHE1 by PPARγ, a putative PPRE element 
containing the hexamer direct repeat 2 (DR2) motif, AGGTCA-GG-AGTTCG, in 
the human NHE1 promoter was identified. Using chromatin immunoprecipitation 
and Light-shift assays, we showed that PPARγ could bind to the hormone 
response element (HRE) within Alu sequences where PPRE is present. Moreover, 
PPARγ agonists, 15d-PGJ2, were shown to induce PPARγ activation and lead to 
downregulation of NHE1 gene expression, at both mRNA and protein level, in 
the breast cancer cell lines tested. This is preceded by increase in cell membrane 
permeability as early as 8h of PPARγ agonists treatment. Interestingly, this was 
associated with an increase of cells in G1 phase at 24h onwards. Downregulation 
of NHE1 could be prevented by selective PPARγ antagonist, GW9662. However, 
vii 
 
GW9662 was not able to rescue cells from PPARγ agonists induced G1 arrest. 
Using ZVAD, N-acetyl cysteine (NAC), FeTPPS and L-NAME, we were able to 
revert G1 arrests induced by PPARγ agonists, whereas ROS scavengers such as 
DMTU and catalase did not show any protecting effects. Hence, we conclude that 
ROS, rather than NHE1, plays essential role in PPARγ agonists induced G1 arrest 
in cells. Besides, our investigations also showed that nitric oxide is the most 
probable ROS involved. On the other hand, overexpressing PPARγ also enhanced 
NHE1 downregulation induced by PPARγ agonists. These PPARγ dependent 
effects were further confirmed by showing that several different glitazones 
induced a decrease in NHE1 protein expression. Finally, PPARγ agonists-induced 
downregulation of NHE1 was shown to sensitize all three breast cancer cell lines 
to cell death induced by paclitaxel, drug commonly used in the treatment of breast 
cancer. Therefore, our data support the induction that NHE1 gene downregulation 
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1.1 Identification of Peroxisome Proliferator-Activated Receptors 
(PPARs) 
 
Peroxisome proliferators are a group of structurally diverse compounds 
that were characterized based on their ability to cause an increase in both the size 
and number of hepatic peroxisomes when administered to rodents (Kliewer et al., 
1994). Peroxisomes are ubiquitous organelles in eukaryotes that function to rid 
the cell of toxic substances. They have a single lipid bilayer membrane that 
separates their contents from the cytosol and contains membrane proteins critical 
for various functions, such as importing proteins into the organelles and aiding in 
proliferation. Peroxisome proliferator-activated receptors (PPARs) were 
originally identified in 1980s in Xenopus frogs as receptors that induce the 
proliferation of peroxisomes in cells, they are intimately connected to cellular 
metabolism (carbohydrate, lipid and protein) and differentiation. In 1990, Isabelle 
et al. cloned a member of the steroid hormone receptor superfamily of ligand-
activated transcription factors and showed that the receptor homologue is 
activated by a diverse class of rodent hepatocarcinogens that causes proliferation 
of peroxisomes, which are peroxisome proliferators (Issemann and Green, 1990). 
These agents subsequently prove to be more versatile in cellular biology and were 
then categorized as members of the nuclear hormone receptor superfamily of 
ligand-activated transcription factors that heterodimerize with the retinoic X 
receptor (RXR) to regulate gene expressions. Indeed, PPARs strictly depend on 
RXRs as DNA-binding partners because they do not function as homodimers or 
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monomers. The nuclear hormone receptor superfamily includes members such as 
the estrogen, thyroid, vitamin D, retinoid acid, glucocorticoid receptors and 
others. The identification of this orphan nuclear hormone receptor activated by 
peroxisome proliferators has shed significant insight into the molecular 























1.2 Retinoic X Receptor (RXR) 
 
 There are three RXR subtypes that originate from three distinct genes: 
RXRα, RXRβ and RXRγ. For each subtype, several isoforms exist that differ 
from one another in their N-terminal A/B domain (Chambon, 1996).  All three 
RXR subtypes are common heterodimerization partners for members of the 
nuclear receptors (Laudet and Gronemeyer, 2002). The first identified 
heterodimeric partners were the thyroid receptors (TRs), retinoic acid receptors 
(RARs), and vitamin D receptor (VDR). The peroxisome proliferators-activated 
receptors (PPARs), liver X receptors (LXRs), farnesoid X receptor (FXR), 
pregnane X receptor (PXR), and constitutively activated receptors (CARs) were 
also identified subsequently. Both in vitro and in vivo approaches have revealed 
that all these nuclear receptors require RXR as a heterodimerization partner for 
their function (Laudet and Gronemeyer, 2002). 
In vitro studies demonstrated that these heterodimers act as ligand-
dependent transcriptional regulators by binding to specific DNA-response 
elements found in the promoter region of target genes and the interaction of RXR 
increases the DNA-binding efficiency of its partner. Importantly, numerous 
heterodimers that contain RXRs can recognize distinct types of response 
elements. For instance, RXR-RAR heterodimers bind to a direct repeat of the 
AGGTCA core motif with a 5-base pair spacing (DR-5) and DR-2, whereas 
RXR-TR and RXR-LXR bind to DR-4, RXR-VDR and RXR-PXR to DR-3 and 
RXR-PPAR to DR-1 (Glass, 1994). Thus, the relative orientation (e.g. direct 
repeat, palindromic, or inverted palindromic configurations) and spacing of the 
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two motifs dictate which particular sets of receptors bind to a given response 
element. Nevertheless, the sequence of the core motif itself, the sequence of the 
spacer, or that of the flanking nucleotides can also play a role in this interaction.  
Recently, it is shown that RARα/RXRα heterodimer is important in 
human inducible nitric oxide synthase (hiNOS) promoter activation, protein 
expression and nitric oxide (NO) production. Human inducible nitric oxide 
synthase (hiNOS) catalyzes nitric oxide (NO) production, which has significant 
effect on tumor progression and cancer therapy. The group has also shown by 
serial deletion and site-directed mutation analysis that there is two half-sites 
retinoic acid response element (RARE) spaced by 5 bp located at -172 to -156 in 
the hiNOS promoter. Subsequently, using electromobility shift assay (EMSA) 
and chromatin immunoprecipitation (ChIP) assays, it was demonstrated that 
RARα/RXRα directly binds to this RARE of hiNOS promoter (Zou et al., 2007).  
On the other hand, RXRs can also form homodimers in vitro that can bind 
to DNA through DR-1 elements (Mader et al., 1993; Mangelsdorf et al., 1991).  It 
has also been demonstrated in vivo that RXR homodimers could activate PPAR 
target genes containing a DR-1 (Ijpenberg, 2004). Nevertheless, the existence and 







1.3 Structure and Functions of Peroxisome Proliferator-Activated 
Receptors (PPARs)  
 
Peroxisome proliferator-activated receptors (PPARs) are characterized by 
three general functional domains: the N-terminal domain (a site for functional 
regulation by phosphorylation), the DNA binding domain and the ligand binding 
domain (Figure 1). The N-terminal domain serves as key determinant of isotype-
selective gene expression. It was shown that the N-terminus of each receptor 
functions in part to limit receptor activity, as deletion of the N-terminus leads to 
non-selective activation of target genes. Of all the domains present, the DNA-
binding domain is the most conserved domain of nuclear receptors. It contains 
two zinc fingers. A crucial role in DNA-binding specificity is played by the P-box 
amino acids located at the carboxyl end of the first zinc finger. On the other hand, 
the ligand-binding domain (LBD) of nuclear receptors plays a pivotal role in the 
transduction of the hormonal signal into transcriptional activation via induction of 
PPAR binding to specific response elements (PPREs), consisting of a direct 
repeat of the nuclear receptor hexameric DNA core recognition motif spaced by 







Figure 1: PPARγ structure and activation (Adapted from Ming-Yue Li, 2006) 
 
Peroxisome proliferator-activated receptor (PPAR) activation is 
potentiated by ligand binding to the PPAR molecule. The ligand binding domain 
contains 11-13 alpha helices that fold to form a hydrophobic pocket where 
ligands can bind. Ligand binding then causes a conformational change in the AF2 
(activation factor 2) helix, which is thought to aid in dimerization and 
transactivation, which can then form heterodimeric complex with other 
transcription factors (e.g., 9-cis-retinoic acid receptor, RXR). The heterodimeric 
complex comprises functional transcription factor that allows binding to 
peroxisome proliferator response elements (PPRE) on DNA (Houseknecht et al., 
2002). Subsequently, various co-activators and co-repressors also fine-tune the 
ability of the activated PPAR: RXR complex to bind to peroxisome proliferator 









Figure 2: Schematic diagram of PPARγ activation. PPARγ functions as 
heterodimer with its obligate partner, RXRα. The dimer interacts with 
coregulators, either coactivators or corepressors. Binding of specific PPARγ 
agonists leads to coactivator recruitment and corepressor release, 
PPARγ/RXRα then binds to the PPRE that is present in the promoters of target 














1.4 Tissue Localization/ Distribution and Importance of 
Peroxisome Proliferator-Activated Receptor (PPAR) Activation 
 
The three peroxisome proliferator-activated receptors (PPARs) that have 
so far been identified are α, δ (also called β, NUC-1 or FAAR) and γ, which 
constitute a distinct subfamily of the superfamily of nuclear hormone receptors. 
These PPARs are activated by naturally occurring fatty acids or fatty acid 
derivatives. In contrast to DNA binding domain that is highly conserved, there is 
poor conservation in ligand-binding domains among the three subtypes. All three 
PPAR subtypes are able to significantly respond to fatty acids, but with different 
yet overlapping specificities. Besides, the functional roles and tissue distribution 
of all three PPARs are also different.  
While PPARα and β stimulate fatty acid catabolism in tissues known for 
their high rates of fatty acid oxidation such as liver, heart, kidney, and brown 
adipose tissue; PPARγ favors fatty acid storage by stimulating triglyceride 
accumulation in adipocytes. Peroxisome proliferator-activated receptor alpha 
(PPARα) is found predominantly in skeletal muscle, liver, heart, and kidney 
whereas PPARβ RNA is more ubiquitously expressed with maximal expression 
in placenta and skeletal muscle. On the other hand, human PPARγ is expressed 
ubiquitously in the insulin-responsive tissue such as skeletal muscle, heart, and 
liver (Mukherjee et al., 1997). The tissue distribution of hPPARγ is important for 
therapeutic activity of drugs targeting the PPARγ/RXR heterodimer such as the 
insulin sensitization drugs used by diabetic patients.  
Among the three PPAR isoforms, PPARγ activation appears to play 
important role in diverse physiological and pathophysiological events including 
9 
 
stimulation of adipocyte differentiation, stimulation of insulin action, regulation 
of lipid metabolism, inhibition of tumor cell proliferation and diverse effects on 
inflammatory processes. Transcriptional activation of the PPARγ/RXR 
heterodimers is enhanced upon binding of a large variety of ligands including 
saturated and unsaturated fatty acids, arachidonic acid derivatives and a wide 
range of synthetic drugs with different subtype specificities. Synthetic ligands for 
PPARγ include the thiazolidinediones (TZD), a class of oral hypoglycemic drugs 
that reduce hyperglycemia and hyperinsulinemia in insulin-resistant states. 
Rosiglitazone (Avandia, Glaxo SmithKline Beecham, Philadelphia, PA) is a TZD 
in clinical use for treatment of type 2 diabetes mellitus. Other TZD class of anti-
diabetes drugs are such as troglitazone (Rezulin; Warner-Lambert Company) and 
pioglitazone (Actos). Activation of PPARγ by these drugs was shown to regulate 
the expression of insulin-responsive genes involved in the regulation of glucose 
and fatty acid metabolism. Rosiglitazone was shown to reduce blood glucose 
levels and hyperinsulinemia in rodent models of type 2 diabetes mellitus, which 
seems to be mediated by the action of insulin in liver, muscle, and fat tissue. 
However, in March 2000, troglitazone was withdrawn from the market by the 
manufacturer following FDA warnings over rare but life-threatening risk of 
hepatotoxicity. Recently, in May 2007, rosiglitazone was reported to be 
associated with significant increase in the risk of myocardial infarction and with 
an increase in the risk of death from cardiovascular causes that had borderline 
significance  (Nissen and Wolski, 2007). Since then, the use of TZD class of 
drugs has triggered much controversy due to its possible side effects. 
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Apart from the synthetic ligand, PPARγ can also be activated by 
endogenous ligand. A metabolite of the eicosanoid prostaglandin J2, 15-deoxy-
∆
12, 14
-PGJ2 (15d-PGJ2) is the most potent natural ligand described so far, with 
reported Kds varying from 325nM to 2.5µM  (Eric Boitier et al., 2003). 
Prostaglandins are arachidonic acid metabolites produced via the cyclooxygenase 
pathway (Figure 3) (Goetzl et al., 1995). Prostaglandin J2 and prostaglandin A2 
arise from the non-enzymatic dehydration in aqueous solutions of prostaglandin 
D2 and prostaglandin E2, respectively (Fukushima, 1990; Fukushima, 1992; 
Noyori and Suzuki, 1993). Albumin accelerates these conversions and catalyzes 
the subsequent isomerization of prostaglandin A2 and prostaglandin J2 to 
prostaglandin B2 and ∆
12
-PGJ2, respectively. In turn, ∆
12


















Both A and J series of prostaglandins display strong antiproliferative 
activities on a broad array of cell lines, including melanoma, retinoblastoma, 
glioma, neutroblastoma, ovarian cancer, leukemia, and HeLa S3 cell lines 
(Fukushima, 1990). Analysis of the structure-activity relationship of 
prostaglandins suggests that the chemical reactivity of anti-tumor prostaglandins 
determines much of their biological activity. It is noteworthy that the most potent 
prostaglandin J2 with respect to their antiproliferative action also binds with the 
highest affinity to PPARγ. As expected for PPARγ ligands, 15d-PGJ2 efficiently 
triggers the differentiation of C3H10T1/2 fibroblasts or PPARγ transfected NIH 
3T3 fibroblasts into adipocytes (Forman et al., 1995; Kliewer et al., 1995). This is 
because high PPARγ expression in adipose tissue is required for its development 
into adipocytes, through regulation of the expression of adipocyte-specific genes, 
such as lipoprotein lipase or the fatty acid transport protein aP2. Besides, PPARγ 
is also expressed in several other tissues in addition to adipose tissue, including 
gut, macrophages, lung, bladder, breast, and prostate, although its function in 
these tissues remains to be elucidated. It was reported that 15d-PGJ2, the 
endogenous PPARγ ligand, is detectable at low picomolar concentrations in the 
medium of 3T3-L1 preadipocytes (Bell-Parikh et al., 2003). This is believed to be 
the endogenous PPARγ ligand concentration. However, this low level of 15d-
PGJ2 concentration has not been shown to lead to PPARγ activation in the 
experimental setting.  
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As of most nuclear hormone receptors, PPARγ translocates from 
cytoplasm to nucleus upon ligand binding and forms heterodimer with RXR. 
PPARγ/RXR complex then constitutes the functional transcription factor and 
binds to a DNA recognition motif composed of a direct repeat (DR) spaced by 
one nucleotide (DR1) with a consensus sequence of RGGTGA-A-AGGTCA 
(Girnun et al., 2002). It is shown that the PPAR DNA-binding activity is 
modulated by the isotype of the RXR heterodimeric partner. Binding of PPAR: 
RXR to strong elements is reinforced when RXRγ is the partner, whereas 
heterodimerization with RXRα is more favourable for binding to weak elements. 
Over the years, functional PPREs have been identified in several genes implicated 
in adipocyte differentiation, most of them involved in lipid storage and control of 
metabolism. During adipocyte differentiation, which ensues from PPARγ 
activation, expression of numerous genes specific for fatty acid metabolism is 
induced. Good examples are aP2, phosphoenol pyruvate carboxykinase (PEPCK), 
acyl CoA synthase (ACS), fatty acid transport protein-1 (FATP-1), and 
lipoprotein lipase (LPL), which are all regulated by PPARγ. Transcription of 
these genes influences the metabolism of fatty acids.  
The conclusive demonstration of the crucial role that PPARγ plays in 
adipogenesis comes from recent observations in PPARγ knock-out (KO) mice. 
PPARgamma -/- mice are shown to be completely devoid of adipose tissue and 
PPARgamma +/- mice are characterized by a decreased adipose tissue mass 
(Kubota et al., 1999; Miles et al., 2000). Besides, injection of PPARgamma -/- 
embryonic mouse cells into wild-type blastocytes produces chimeric mice in 
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which adipose tissue is composed exclusively of PPARgamma +/+ cells. These 
experiments demonstrate the importance of PPARγ in ensuring the development 
of adipose tissue (Rosen et al., 1999).  
Using microarray analysis performed on differentiated 3T3-L1 mouse 
adipocytes treated with various PPARγ ligands, a large number of novel 
candidate genes were again identified. Two such genes, activating transcription 
factor 3 (ATF3) and PPARγ coactivator-1 alpha (PGC-1α), were confirmed to be 
upregulated by PPARγ ligand treatment. Initial characterization of their 
expression patterns in adipocytes was performed. The oxidized low-density 
lipoprotein receptor 1 (OLR1) was also shown to be dramatically upregulated by 
TZDs in adipocytes. OLR1 was subsequently shown to be a direct PPARγ target 
gene. It contains four distinct PPAR response elements in its promoter, and is 
transcriptionally regulated by the exchange of corepressors for coactivators in the 
presence of a PPARγ ligand. In addition, TZDs also markedly stimulate the 
uptake of oxidized low-density lipoprotein (oxLDL) into adipocytes, in part 
through the induction of OLR1. Increasing OLR1 expression, either by TZD 
treatment or by adenoviral gene delivery, significantly augments adipocyte 
cholesterol content and enhances free fatty acid uptake. On the other hand, fusion 
of the potent viral transcriptional activator VP16 to PPARgamma2 (VP16-
PPARγ) created a transcription factor that constitutively and dramatically 
activated transcription of PPARγ-responsive genes in the absence of ligand. 
Forced expression of VP16-PPARγ in 3T3-L1 preadipocytes using retroviral 
vectors led to adipogenesis in the absence of standard differentiating medium or 
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any exogenous PPARγ ligand (Guan et al., 2002). Hence, the role of PPARγ as an 
























1.5 Peroxisome Proliferator-Activted Receptor Gamma (PPARγ) 
in Adipogenesis and Cell Cycle Regulation 
 
In this study, PPARγ is our primary focus. The human PPARγ gene, 
which has nine exons and extends over more than 100kb of genomic DNA, is 
mapped to a locus on chromosome 3p25. In contrast to mouse in which only two 
PPARγ isoforms have been described, four PPARγ mRNA isoforms have been 
identified in human. This is due to PPARγ gene containing four promoters that 
yield three RNA isoforms, γ1, γ2, γ3 and γ4 by alternative promoter usage and 
splicing. Whereas the PPARγ1, γ3 and γ4 mRNAs give rise to an identical protein 
product, the PPARγ2 mRNA encodes for the PPARγ2 protein, which contains 28 
additional amino acids.  
Figure 4: Organization of the PPARγ gene expression. Four different mRNA 
are transcribed due to alternate start site as well as alternative splicing. 
Transcript type 1, 3 and 4 encode a single protein PPARγ1; whereas PPARγ2, 
encoded by the type 2 transcript, has 30 additional amino acids in amino 




Peroxisome Proliferator-Activate Receptor gamma (PPARγ) expression is 
differentially regulated in a tissue-specific manner. In humans, PPARγ is 
expressed in multiple tissues such as the breast, colon, lung, ovary, and placenta. 
PPARγ2 is most abundantly expressed in adipocytes and is relatively specific for 
this tissue. While PPARγ1 is also expressed at high level in adipocytes, it is also 
found at significant but lower levels in a number of other tissues, including 
muscles. Ranjan Mukherjee et al. has shown via transcriptional response in a 
cotransfection assay that PPARγ1 and  PPARγ2 are activated by BRL 49653 with 
an EC50 of approximately 100nm and by 15-deoxy-∆
12, 14
-PGJ2 (an endogenous 
PPARγ ligand) with an EC50 around 3µM. (Mukherjee et al., 1997) 
Previous studies have shown that PPARγ plays important roles in 
adipocyte differentiation. Under normal circumstances, differentiation and cell 
proliferation are mutually exclusive. However, in the context of adipogenesis, 
there is in fact a close relationship between cell proliferation and differentiation. 
One of the first events occurring during adipogenesis is re-entry into cell cycle of 
growth-arrested adipocytes following hormonal induction. After several rounds of 
clonal expansion, cells arrest proliferation again and undergo terminal adipocyte 
differentiation. In fact, in the first hours of adipocyte differentiation, an increase 
in the E2F activity has been observed (Richon et al., 1997). E2Fs are transcription 
factors which regulate the expression of genes involved in DNA synthesis. 
Consequently, expression of genes, such as cyclin D1, c-Myc, or cyclin E, have 
been observed to increase in the early stages of adipogenesis (Reichert and Eick, 
1999). Hence, there is undoubtedly a cross-talk between the cell cycle and the 
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adipocyte differentiation machinery. However, the shift in gene expression 
observed during the transition between preadipocyte proliferation and adipocyte 























1.6 Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) 
And Its Antiproliferative Effects in Tumor Cells 
 
 The antiproliferative effects of PPARγ go further than participation in the 
cell cycle arrest during the adipocyte differentiation process. In fact, PPARγ 
expression is not restricted to adipose tissue. It is also being expressed in several 
other cell types, especially for PPARγ1. PPARγ expression is observed at high 
levels in different cancers including colon (Bull, 2003), breast (Jiang et al., 2003), 
bladder (Yoshimura et al., 2003), prostate (Smith and Kantoff, 2002), head and 
neck (Jaeckel et al., 2001), cervical (Han et al., 2003) and endometrial cancer 
(Tong et al., 2000). Furthermore, it has been reported that PPARγ expression is 
increased in several epithelial cancer cells. Whereas the physiological function of 
PPARγ in normal epithelial cells is largely unknown, PPARγ activation was 
reported to inhibit the proliferation of malignant cells from different lineages such 
as liposarcoma (Tontonoz et al., 1997), breast adenocarcinoma (Elstner et al., 
1998; Mueller et al., 1998b), prostate carcinoma (Butler et al., 2000), colorectal 
carcinoma (Brockman et al., 1998; Sarraf et al., 1998), non-small cell lung 
carcinoma (Motomura et al., 2000), bladder cancer cells (Guan et al., 1999), and 
gastric carcinoma cells (Sato et al., 2000).  
 
1.6.1 Prostate Cancer 
 
The physiological function of PPARγ in normal epithelial cells is largely 
unknown. However, high PPARγ expression and activation were reported to 
inhibit the proliferation of prostate cancer cells and also other lineages. These 
observations suggest that induction of differentiation by activation of PPARγ, by 
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acting as inhibitors of malignancy progression, may represent a promising novel 
therapeutic approach for cancer. In fact, members of the prostaglandin J series 
have been shown to cause G1 arrest at lower doses and at higher concentrations 
cause G2-M arrest leading to apoptosis (Kim et al., 1993; Fukushima et al., 
1994). Rachel Butler et al. also showed that 15d-PGJ2, an endogenous PPARγ 
ligand, induces nonapoptotic cell death in human prostate cancer cells. Both 
mitochondrial and plasma membrane disturbances are involved in this cell death 
mechanism (Butler et al., 2000), which are indicative of type 2 (autophagic), 
nonapoptotic programmed cell death.  
Treatment of advanced prostate cancer patient with the PPARγ agonist 
troglitazone has shown to result in a high incidence of stabilization of prostate-
specific antigen (PSA) level. Forty-one men with histologically confirmed 
prostate cancer and no symptomatic metastatic disease were treated orally with 
troglitazone. An unexpectedly high incidence of prolonged stabilization of PSA 
was observed in patients treated with troglitazone (Mueller et al., 2000). PSA is a 
widely used marker for the diagnosis and management of patients with prostate 
cancer. However, contradictory results were observed in another study. The study 
conducted showed that rosiglitazone, another synthetic PPARγ ligand that 
belongs to the TZD class, has no effects on disease progression in patients. In this 
study, men with histologically confirmed prostate carcinoma, no recent hormone 
therapy, rising serum PSA level after radical prostatectomy and/or radiation 
therapy, and no radiographic evidence of metastases were assigned randomly to 
receive either oral rosiglitazone (4mg twice daily) or placebo. The biological 
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activity of rosiglitazone was assessed using change in PSA doubling time 
(PSADT) as the primary outcome variable. The results showed that rosiglitazone 
did not increase PSADT or prolong the time to disease progression more than 
placebo in men with a rising PSA level after radical prostatectomy and/or 
radiation therapy (Smith et al., 2004). Hence, the group hypothesized that under 
certain circumstances, PPARγ could be insensitive to ligand activation in prostate 
cancer, probably due to the repression of PPARγ activity by the action of 
upstream events. To further investigate this possibility, Annicotte et al. showed 
that inhibition of histone deacetylase (HDAC) activity is required to achieve 
maximal PPARγ activation in prostate cancer cells. The group has managed to 
characterize PPARγ-HDAC3 direct interaction and showed that PPARγ is part of 
HDAC3-containing repressor complex in the presence of PPARγ ligand (Fajas et 
al., 2002). Apart from regulating expression of cell cycle regulator proteins, 
Annicotte et al. also showed that PPARγ could exert its antiproliferative effects 
through regulation of E-cadherin expression. In contrast to classical PPARγ target 
genes, regulation of E-cadherin expression in response to PPARγ ligands at both 
the promoter and RNA level requires the presence of HDAC inhibitors to fully 
achieve maximal stimulation (Annicotte et al., 2006). E-cadherin is known to 
inhibit metastasis and invasion of prostate cancer cells through maintenance of 
the adherens junctions important for epithelial cell-cell adhesion and inhibition of 
epithelial-to-mesenchymal transition, which is a required event in cancer 
progression. Hence, the group suggests that sensitivities of PPARγ repression to 
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HDAC are different depending on the context of the promoter of the PPARγ 
target gene.  
 
1.6.2 Colon Cancer 
 
 Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) is also 
expressed at high levels in colonic epithelial cells and colon cancer cells. Similar 
to prostate cancer, it was also shown that activators of PPARγ suppress the 
growth response of colon cancer cells (Sarraf et al., 1998) and activation of 
PPARγ was documented to lead to inhibition of anchorage independent growth of 
colon cancer cells (Brockman et al., 1998). In the process, certain genes were 
observed to be upregulated. In HT-29 colon cancer cells, it was shown that 
activation of PPARγ results in upregulation of differentiation marker genes such 
as villin and intestinal alkaline phosphatase (Kubota et al., 1999). Villin is an 
actin-binding protein that is expressed mainly in the brush border of the 
epithelium; whereas alkaline phosphatase  is a hydrolase enzyme responsible for 
removing phosphate groups from many types of molecules, including nucleotides, 
proteins, and alkaloids. They are both markers for enterocyte differentiation. 
Upregulation of these marker genes suggests that PPARγ induced differentiation 
might be involve in growth retardation observed in these cells.  
It was then showed that the occurrence of apoptosis induced by PPARγ 
ligands in colon cancer cells was sequentially accompanied by reduced levels of 
NF-kB and Bcl-2. Over-expression of Bcl-2 significantly protected the cells from 
apoptosis (George G. Chen, 2001). Besides, T Shimada et al. also showed that 
22 
 
PPARγ ligand induced apoptosis in HT-29 cells was associated with 
downregulation of c-myc expression and upregulation of c-jun and gadd153 
expression. This was antagonized by signaling mediated through PI3-kinase 
(Shimada et al., 2002).  This suggests the involvement of Akt pathway in PPARγ 
ligand induced apoptosis in colon cancer.  
However, clinical trials conducted using troglitazone on colorectal cancer 
patient has not shown promising results. A phase II study of troglitazone was 
conducted in patients with chemotherapy-resistant metastatic colorectal cancer. 
Patients with metastatic colorectal cancer were treated with troglitazone. Patients 
were followed up for evidence of toxicity, tumor response and survival. However, 
no objective tumor responses were noted in the trial. Hence, the group concluded 
that troglitazone might not be an active agent for the treatment of metastatic 
colorectal cancer (Kulke et al., 2002). However, failure of PPARγ ligands 
mediating expected growth inhibitory effects in clinical trials conducted in 
colorectal cancer patient may simply be explained by possible loss-of-function 
mutation of PPARγ gene in cancers. To further investigate this possibility, Gupta 
et al. identified four human colon cancer cell lines that do not undergo growth 
inhibition or induce markers of differentiation after exposure to PPARγ agonists. 
Sequence analysis of the PPARγ gene revealed that all four cell lines contain a 
previously unidentified point mutation in the ninth α-helix of the ligand binding 
domain at codon 422 (K422Q). The mutant receptor did not exhibit any defects in 
DNA binding or retinoid X receptor heterodimerization and was transcriptionally 
active in an artificial reporter assay. However, only retroviral transduction of the 
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wild-type (WT), but not mutant, receptor could restore PPARγ ligand-induced 
growth inhibition and differentiation in resistant colon cancer cell lines (Gupta et 
al., 2003). Thus, PPARγ mutation could be another reason for the 
nonresponsiveness observed in PPARγ ligands treated patients.  
 
1.6.3 Breast Cancer 
 
Breast cancer is the most common cancer among women worldwide. Breast 
cancer is a complex disease that results from a multi-stage process involving the 
deregulation of a number of different signaling cascades. It is also the most 
frequent non-skin cancer to affect women worldwide, and remains one of the top 
public health burdens. There are about 212,930 new cases of breast cancer 
diagnosed every year, and 40,840 related deaths have been reported in the United 
Sates alone (Jemal et al., 2005). However, improvements in hormonal and 
cytotoxic therapies have not led to sustained remission or cure in advanced breast 
cancer. Hormonal therapy works to reduce the effect of estrogen on the body so 
that it can no longer turn on the growth of hormone-receptor-positive breast 
cancer cells. The idea is to starve breast cancer cells of estrogen which tumor 
cells need to grow. The different treatments either block hormone receptors, 
eliminate hormone receptors, or lower estrogen levels in the body. Although anti-
estrogens have provided the most effective endocrine therapy for advanced breast 
cancer, therapeutic choices are limited for ERα-negative tumors, which are often 
aggressive and metastatic. Also, only about two-thirds of ERα-positive breast 
cancers respond to estrogen. The limited therapeutic possibilities for therapy of 
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breast cancer thus provide strong stimulus for exploring new approaches. 
Recently, it was shown that human breast cancer cell lines as well as primary and 
metastatic breast adenocarcinomas expresse high level of PPARγ. Ligand 
activation of PPARγ was shown to cause inhibition of proliferation and extensive 
lipid accumulation in cultured breast cancer cell lines (Elstner et al., 1998). 
Epidemiological data suggest that the incidence of breast cancer is related to 
consumption of a diet high in fat. Hence, inhibition of fat metabolism in these 
cells is associated with inhibition of growth and apoptosis. However, the 
mechanism by which PPARγ complex leads to apoptosis of cells is unknown. 
Elstner et. al. have recently found that breast cancer cells express high levels of 
PPARγ, whereas normal epithelial cells lining the mammary ducts express only a 
low level of this receptor (Elstner et. al., 1998). This finding suggests a possible 
role for ligand-activated PPARγ as an anti-tumor agent in breast cancer. Since 
then, several independent studies have identified PPARγ target genes in breast 
cancer cell lines. It was reported that the overexpression of PPARγ is caused by 
the use of a tumor-specific promoter in breast cancer cells that is distinct from the 
promoter used in normal epithelial. Phase II clinical trial using PPARγ ligands 
has also been performed as a novel therapy for advanced breast cancer patients 
(Burstein et al., 2003). However, PPARγ activation by troglitazone used in the 
trial was shown to have little apparent clinical value among patients with 
treatment-refractory metastatic breast cancer.  
The inhibition of cell growth observed in human breast cancer cells 
treated in vitro with PPARγ ligands was found to be accompanied by a profound 
25 
 
decrease of Bcl-2 gene expression and a marked increase in apoptosis (Elstner et. 
al., 1998). Elstner et al.  reported that combination of a PPARγ-specific ligand, 
troglitazone with either a RAR-, RXR-, or RAR/RXR-specific ligand resulted in 
the inhibition of the clonal proliferation of breast cancer cell lines, independent of 
their expression of bcl-2, p27
kip1
, p53, BRCA1, bag-1, c-erbB2, and ERα. 
However, apoptosis was only observed in human breast cancer cell lines that 
expressed high levels of bcl-2. Data shown by Carl E. Clay et al. also suggests 
that apoptosis, not differentiation, is the primary biological response for PPARγ 
activation by 15d-PGJ2 in some breast cancer cell lines (Carl E. Clay, 1999). 
Besides, PPARγ ligands were also shown to inhibit proliferation of breast cancer 
cells by repressing cyclin D1 expression (Wang et. al., 2001), enhanced tumor 
suppressor gene, BRCA1 gene expression (Pignatelli et. al., 2003), dramatically 
up-regulated PTEN gene expression ( Patel et. al., 2001), and inhibit Erb 
signaling pathway (Pignatelli et. al., 2001). Recently, T Suzuki et al. also showed 
that ligand-mediated PPARγ activation caused the suppression of a portion of 
estrogen-mediated transactivation or inhibition of estrogen-mediated proliferation 
in MCF-7 cells. PPARγ immunoreactivity was also detected in carcinoma cells in 
42% of breast cancer tissues, and this is positively associated with ERs, PR, 
RXRs, p21 or p27, and negatively correlated with histological grade or COX2. 
These findings suggest that PPARγ is mainly expressed in well-differentiated and 
ER-positive breast cancers, and in part, plays a role as a modulator of estrogenic 
actions (Suzuki et al., 2006). Finally, a very recent study also showed that the 
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PPARγ ligand, troglitazone induces cellular acidosis by inhibiting Na+/H+ 

























1.7 Sodium/ Hydrogen Exchanger 1 
 




 exchanger 1 (NHE1) 
gene expression as a possible mechanism involved in reactive oxygen species 
(ROS)-mediated regulation of tumor cells’ response to apoptosis. Our lab has 
recently shown that intracellular superoxide anion level is a major signal for the 
activation of the NHE1 gene promoter that leads to increase in NHE1 protein 
expression and cells’ resistance to apoptotic triggers (Akram et al., 2006). This 
increase in superoxide anion level is usually accompanied by a decrease in 
hydrogen peroxide level and vice versa. The role of NHE1 in apoptosis was also 
identified in leukemic cells. It was demonstrated that apoptotic death in this cell 










exchanger inhibitor which binds to N-terminal region of NHE1 
and inhibits its activation (Yu et al., 2000). 
The NHE family of ion exchangers includes nine isoforms (NHE1-NHE9) 
that function in an electroneutral exchange of intracellular H
+
 for extracellular 
Na
+
. All NHE isoforms share a similar topology: an N-terminus of 12 
transmembrane (TM) α-helices that collectively function in ion exchange, and a 
C-terminal cytoplasmic regulatory domain that modulates transport activity by 
the TM domain (Putney et al., 2002). The human NHE1 protein is an 815 amino 
acid plasma membrane glycoprotein that is widely distributed in mammalian 
tissues. Proton efflux is a major factor in pHi maintenance as normal cellular 
metabolism generates an intracellular acid load. NHE proteins are activated by 
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acidic cellular conditions to catalyze the electroneutral exchange of 1 
extracellular sodium ion for 1 intracellular proton and as such, constitute a key 
component in the protection against cellular acidosis. This exchange process is 
dependent on extracellular Na
+
 and ATP. Among the nine isoforms of NHEs 
identified to date, NHE1 is the most likely candidate to be involved in 
intracellular acidification during ROS-induced apoptosis. There are several 
reasons for this. Firstly, NHE1 is ubiquitously expressed and plays a central 
housekeeping role in pHi homeostasis (Putney et al., 2002). Secondly, it has been 
reported that the activation of Fas inhibits NHE1 activity and that the 
pharmacological inhibition of NHE1 accelerates Fas-mediated apoptosis (Lang et 
al., 2000). Thirdly, it was recently shown that the anti-cancer drug, paclitaxel 
(Taxol), induces apoptosis via the inhibition of NHE1 (Reshkin et al., 2003). 
Paclitaxel is a chemotherapy that is given as a treatment for some types of cancer, 
such as ovarian, breast and lung cancer. Interestingly, whereas inhibition of 
NHE1 promotes apoptotic cell death, the stimulation of NHE1 activity promotes 
cell proliferation (Grinstein et al., 1989). Paclitaxel works by binding to 
microtubules and inhibits their depolymerization into tubulin. This means that 
paclitaxel blocks a cell’s ability to break down the mitotic spindle during mitosis. 
With the spindle still in place the cell can’t divide into daughter cells. This will 
thus induce cells to undergo apoptosis. Furthermore, not only have studies shown 
that transformed cells exhibit greater NHE1 activity than their non-transformed 
counterparts (Siczkowski et al., 1994), it has also been reported that NHE1-
dependent intracellular alkalinization plays an essential role in malignant 
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 Exchanger is known to exist as dimers and the NHE1 isoform 





(Bullis et al., 2002).  It is involved in intracellular pH regulation and control of 
cell volume (Fernandez et al., 2001). It is also activated in cells stimulated with 
numerous agonists such as epidermal growth factor, thrombin, phorbol esters, and 





concurrently with a rise in intracellular pH which signifies increase in NHE1 
activities. Angiotensin II, commonly known as vasoconstrictor agent, can activate 
extracellular signal-regulated kinase (ERK) which in turn stimulates NHE1 
phosphorylation and activity. In fact, ERK 1/2 activation appears to be a common 
denominator in the process of NHE1 activation by several growth factors. This is 
prudent as MEK1/ERK1/2 pathway inhibition with PD98059 or use of a 
dominant negative ERK1 construct blocks activation of the exchanger by α1-
adrenergic receptor agonists, serum, endothelin, platelet-derived growth factor, 
thrombin and phorbol esters among others. PD98059 is a potent and selective cell 
permeable inhibitor of MAP kinase kinase (MEK). It selectively blocks the 
activation of MEK, thereby inhibiting the phosphorylation and the activation of 
MAP kinase. Activation of NHE1 by serum was dependent on phosphorylation of 
serine 703 (Ser(P)
703
) by p90 ribosomal S6 kinase (RSK), which in turn was 
directly regulated by ERK1/2 (Lehoux et al., 2001).  
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1.8 Peroxisome Proliferator-Activated Receptor (PPARγ) and 
NHE1 
 
As the master regulator of fat-cell formation, PPARγ is required for the 
accumulation of adipose tissue and hence contributes to obesity. However, 
PPARγ ligands are clinically effective antidiabetic drugs, although side effects 
limit their utility. Hence, many questions arose if PPARγ can be targeted with 
greater benefit and with less risk to patients? The answer depends upon the basic 
biology of PPARγ, and the possibility of selectively modulating the activity of 
this nuclear receptor in a tissue- and target-gene-specific manner.  
The aim of this research is to characterize PPARγ induced regulation of 
sodium hydrogen exchanger 1 (NHE1) in breast cancer cell lines. Previous 
findings have suggested that treatment with PPARγ-specific ligands may be a 
target for differentiation-based therapy for breast cancer cells which express high 
level of PPARγ protein. Previous findings also suggest that breast cancer cells 
express higher level of PPARγ compared to normal breast cells. Furthermore, 
PPARγ haploinsufficiency (PPARγ+/-) also confers increased susceptibility to 
dimethylbenz(a)anthracene-induced mammary carcinogenesis (Nicol et al., 
2004).  
In the context of our research, MCF-7, MDA-MB231 and T47D cells 
provide excellent in vivo model system to study human breast cancer and effects 
of PPARγ ligands on NHE1. MCF-7 cell line was established from the pleural 
effusion of a patient who was diagnosed with adenocarcinoma of the breast 
(Soule et al., 1973). The MCF-7 line also retains several characteristics of 
differentiated mammary epithelium including ability to process estradiol via 
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cytoplasmic estrogen receptors and the capability of forming domes. Elevated 
plasma estrogen concentrations are implicated in inducing breast cancer 
(Gustafsson and Warner, 2000; Munster et al., 2001). On the other hand, MDA-
MB231 is a highly metastatic breast carcinoma cells. It is negative for estrogen 
receptors and express higher levels of PPARγ compared to MCF-7 and T47D. 
Next, T47D is established from the pleural effusion of ductal carcinoma of the 
breast. These cells carry receptors for a variety of steroids. The reported rank 
order of PPARγ protein expression in breast cancer cell lines was shown to be the 
following: BT20 > BT474 > SKBR3 > ZR-75-1 > MDA-MB-436 >MCF-7 > 
MDA –MB-231 > T47D (Elstner et al., 2002). However, there are also findings 
that suggest otherwise. As for the in vivo normal breast cells model, HTB125 and 
MCF10 cell lines were chosen. HTB125 and MCF10 were both derived from 
normal breast tissue peripheral to an infiltrating ductal carcinoma.  
We examined the 5’ proximal promoter region of the human NHE1 gene 
and identified a putative AluRRE (Alu Receptor Response Element) within the 
human NHE1 promoter region. Alu elements are functional pol III genes with 
internal A and B box promoter elements and are probably derived from 7SL 
genes. The Alu sequences have been amplified and reinserted throughout the 
genome by a retroposition process involving a RNA intermediate. During the 
preceding 30-60 million years of primate evolution, a succession of source genes 
has given rise to extensive Alu subfamilies whose members share a few common 
diagnostic base changes, indicative of mutations in the parental source gene. 
Except for these few base changes, most of the source gene sequence has been 
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conserved throughout this period. An analysis of the known Alu sequences 
indicates that mutations have been strongly suppressed at a number of positions, 
implying that Alu sequences have sequence-dependent functions important for 
primate evolution. One postulated function is that these inserts influence the 
expression of nearby genes (Vansant and Reynolds, 1995).  
Alu element contains cluster of four hexamer half-sites recognized by 
various nuclear receptors, termed an Alu receptor response element (AluRRE). 
These hexamers are organized as direct repeats with spacing of 2-4-2 base pairs. 
The hexamer 1/2 contains estrogen and SP1 (Stimulatory Protein) binding site, 
whereas hexamer 3/ 4 pair is recognized by retinoic receptor as a heterodimer 
with retinoic X receptor, and the middle DR-4 pair (hexamer 2/ 3) is recognized 
by thyroid hormone receptor.  
Functional analysis from a recent study showed that Alu elements that are 
located in the promoter region of genes are functionally active (Kumar et al., 
2004). A functional myeloperoxidase (MPO) promoter polymorphism, -463GA, 
has been associated with incidence or severity of inflammatory diseases, 
including atherosclerosis and Alzheimer’s disease, and some cancers. The 
polymorphism is within an Alu element encoding four hexamer repeats 
recognized by nuclear receptors (AluRRE). Kumar et al. showed that PPARγ 
agonists strongly regulate MPO gene expression through the AluRRE. This was 
observed with rosiglitazone and three other PPARγ ligands of the 
thiazolidinedione (TZD) class, as well as the natural prostaglandin J2. 
Surprisingly, DNA sequence of AluRRE in the human NHE1 promoter region is 
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similar to the AluRRE that precedes myeloperoxidase (MPO) gene. Hence, it is 
very likely that PPARγ agonists may also regulate NHE1 gene expressions and 
activities by binding to PPRE in the human NHE1 promoter. 
Given that expression of PPARγ is increased in breast cancer cells and 
PPARγ agonists induce cellular acidosis via inhibition of sodium hydrogen 
activity, together with our findings that ROS regulates expression of NHE1 gene, 
we sought to investigate to show if human NHE1 is a transcriptional target of 
PPARγ. In addition, effects of PPARγ on intracellular ROS levels will also be 
investigated in this study to provide a more conclusive hypothesis on PPARγ  



















2. MATERIALS AND METHODS 
2.1  Reagents 
 
Roswell Park Memorial Institute (RPMI) 1640 medium, Dulbecco’s Modified 
Eagle’s Medium (DMEM), Fetal bovine serum (FBS), charcoal stripped fetal 
bovine serum (CS-FBS), phosphate buffered saline (PBS), trypsin and L-
glutamine were from Hyclone, UT, USA. Phenol free RPMI and Hoechst 34580 
were purchased from Invitrogen. Mammary Epithelial Growth Medium (MEGM) 
was from Clonetics, La Jolla, CA. Pepstatin A, phenylmethanesulfonyl fluoride 
(PMSF), leupeptin, propidium iodide (PI), crystal violet and bovine serum 
albumin (BSA) were supplied by Sigma-Aldrich, LO, USA. Aprotinin was 
purchased from Applichem, Darmstadt, Germany. Gentamicin sulphate was 
purchased from BioWhittaker, Walkersville, MD. Methanol and sodium dodecyl 
sulphate (SDS) were purchased from Merck, Darmstadt, Germany. Cell lysis 





Isoform NHE1 Monoclonal antibody was purchased from Chemicon 
International. Mouse anti-peroxisome proliferator activated receptor gamma 
(PPARγ) and mouse anti-estrogen receptor alpha monoclonal antibody were 
purchased from Santa Cruz. Stabilized goat anti-mouse horseradish peroxidase 
(HRP) and goat anti-rabbit horseradish peroxidase (HRP) were obtained from 




2.2 Cell Culture  
Monolayer cultures of MCF-7, MDA-MB231 and T47D human breast cancer 
cells were grown in RPMI supplemented with 10% fetal bovine serum (FBS), 
2mM L-glutamine (Hyclone) and 0.05mg/ml gentamicin (BioWhittaker). 
Glutamine decomposes in culture medium in a time and temperature dependent 
manner. At 37
0
C, glutamine’s half life is eight days; at 4
0
C, its half life is 40 
days. Ammonia is the product of decomposition, it is potentially toxic. Hence, 
RPMI needs to be supplemented with glutamine. Gentamicin is an antibiotics. 
The three breast cancer cell lines were subcultured in 75cm
2
 flasks (NUNC, NY, 
USA) every three days with a subculture ratio of 1:3. For experiments, cells were 
resuspended from culture flasks using trypsin. Cells were then pelleted by 
centrifugation at 1200rpm and the supernatant removed. Cells were resuspended 
and counted using a haemocytometer before being seeded into six-well plates 
(Falcon, NJ, USA) at 3 x 10
5
 cells per well for MCF7 and MDA-MB231, 2.5 x 
10
5 
for T47D in RPMI supplemented with 10% charcoal stripped fetal bovine 
serum (CS-FBS), 2mM L-glutamine and 0.05mg/ml gentamycin. Charcoal-
stripped serum is routinely used in estrogenic and retinoid studies as it allows 
depletion of serum hormones or serum retinoids in the culture medium, therefore, 
any activation seen is truly due to the compounds added (Pfahl et al., 1990). The 
cells were then incubated for 48h to allow for attachment prior to deprivation in 
phenol free RPMI for 24h. Cells were incubated in a 37
0
C and 5% CO2 
atmosphere. At the time of drug additions, medium was removed and replaced 
with fresh phenol free RPMI medium containing no serum, but supplemented 
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with 2mM L-glutamine and 0.05mg/ml gentamycin. Cells were treated for 24h 
unless specified. 
Monolayer cultures of HTB125 normal breast cells were grown in DMEM 
supplemented with 10% fetal bovine serum (FBS), 2mM L-glutamine, 0.05mg/ml 
gentamicin and 30ng/ml epidermal growth factor (EGF). The cells were 
subcultured in 75cm
2
 flasks (NUNC, NY, USA) every 6 days with a ratio of 1:2. 
For experiments, cells were seeded into six-well plates (Falcon, NJ, USA) at 0.24 
x 10
5 
in DMEM supplemented with 10% charcoal stripped fetal bovine serum 
(CS-FBS), 2mM L-glutamine, 0.05mg/ml gentamicin and 30ng/ml epidermal 
growth factor (EGF).  
Monolayer cultures of MCF10 cells were grown in MEGM supplemented with 
10% fetal bovine serum (FBS), 2mM L-glutamine and 0.05mg/ml gentamicin. 
The cells were subcultured in 75cm
2
 flasks (NUNC, NY, USA) every 3 days with 
a ratio of 1:3. For experiments, cells were seeded into six-well plates (Falcon, NJ, 
USA) at 1.0 x 10
5 
in MEGM supplemented with 10% charcoal stripped fetal 













All cells were transfected using Calcium Phosphate Mammalian transfection kit 
(Clonetech Laboratories Inc., Palo Alto, CA). In brief, 0.25 X 10
6 
cells/well were 
plated in 6-well plates 48h prior to transfection. At 2h before transfection, cell 
culture medium was changed to DMEM supplemented with 10% FBS, 2mM L-
glutamine and 0.05mg/ml gentamicin. To prepare the transfection mixture, the 
calculated amount of DNA was diluted in sterile dH20 in a microfuge tube, 
followed by the addition of 12.4µl of 2.5M CaCl2 in a total amount of 100 
µl/well. The DNA-CaCl2 solution was then mixed drop wise with DNA 
precipitation buffer (100 µl) while gently vortexing, and the mixture was added to 
the medium of each well, that is, 200 µl per well. After 16h incubation, cells were 
washed with PBS and normal tissue culture media was then added for another 8h 
prior to deprivation of cells in phenol free medium without serum 
supplementation for 18h. The cells were then subjected to various treatments as 
described previously. 
2.4 Plasmid Constructs 
Plasmid pcmX-mPPARγ, a cDNA clone encoding the mouse PPARγ was a kind 
gift from Dr. Ronald M. Evans, The Salk Institute for Biological Studies, San 
Diego, CA, USA. Plasmid pCMV-HA-NHE1 encoding N-terminal hemagglutinin 
(HA) epitope tagged-NHE1 was kindly provided by Dr. Jeffrey R. Schelling, 
MetroHealth Medical Centre, Cleveland, Ohio, USA. Human catalase cloned into 
the eukaryotic expression plasmid pCI-neo was a kind gift of Dr. David Lambeth, 





21-nucleotide RNAs were chemically synthesized (Qiagen). 50-GAU AGG UUU 
CCA UGU GAU C sequence was used to silence NHE1 gene transcription 
(siNHE1) and 50-AGC UUC AUA AGG CGC AUG CTT (luciferase gene 
sequence inverted) sequence was used as a control (control si).  
 
2.6 Treatment of Cells with 15d-Prostaglandin J2, Rosiglitazone, 
Troglitazone, ciglitazone, GW9662 and paclitaxel 
15d-Prostaglandin J2 (15d-PGJ2) was purchased from Alexis at concentration of 
1mg/ml. It was added to complete medium to attain the indicated final 
concentrations. A stock solution of 10mM Rosiglitazone, Ciglitazone, 
Troglitazone (Cayman, USA) was prepared by diluting 5mg of solid 
rosiglitazone, ciglitazone, troglitazone in calculated amount of DMSO, depending 
on the molecular weight of the compound. Various concentrations of glitazones 
were then prepared by diluting the stock solution of 10mM glitazones with 
complete medium to attain the indicated final concentrations.  
For GW9662, a stock solution of 100mM GW9662 (Cayman, USA) was prepared 
by diluting 5mg of crystalline solid GW9662 in 0.18ml DMSO. Various 
concentrations were then prepared by diluting the stock solution with complete 
medium to obtain the indicated final concentrations.  
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2.7 Measurement of Cell viability via crystal violet and 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
Assay 
MCF-7 (1.5 X 10
5
cells/well), MDA-MB231 (1.5 X 10
5
 cells/well) and T47D 
(1.25 X 10
5
 cells/well) were plated in 12-well plates. Experiments were set up as 
described previously. Cell growth/cytotoxicity was assessed by determining the 
number of intact cells over time using the crystal violet uptake assay. At the end 
of drug treatment, medium was removed from wells. The cells were then washed 
once with 1x PBS. This was followed by incubation with 0.5ml of crystal violet 
solution (0.75% crystal violet, 50% ethanol, 1.75% formaldehyde, 0.25% NaCl) 
for ten minutes. Excess crystal violet solution was carefully washed away with 
distilled water for several times and the wells were left to air-dry. The remaining 
crystals were dissolved in a 1% SDS in 1 X PBS solution. The amount of dye 
released reflects the quantity of intact cells present in each well. 50µl of cell 
lysate from each well was transferred into separate wells of a transparent 96-well 
microtitre plate. The quantity of crystal violet present in the cell lysate was 
determined by measuring its absorbance at 595nm using the Spectrofluoro Plus 
spectrophotometer (TECAN, GmbH, Grödig, Austria). 
Another assay that was used to assess cell viability is MTT. Similar to crystal 
violet assay, MTT is also a functional assay. Similar experiment set up was 
performed. 5mg/ml MTT was first dissolved in PBS and filtered sterilise. MTT 
assays is based on the ability of mitochondrial dehydrogenase enzyme from 
viable cells to cleave the tetrazolium rings of the pale yellow MTT and form a 
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dark blue formazan crystals which is largely impermeable to cell membranes, 
thus resulting in its accumulation within healthy cells. Three hours before the end 
of drug incubation, MTT solution was added into each well containing cells at 1: 
10 dilution. MTT added cells were then incubated at 37
0
C with 5% CO2. Three 
hours after the incubation, medium was removed with needle and syringe prior to 
addition of DMSO to each well to solubilise cells. The number of surviving cells 
is directly proportional to the level of formazan product created. The quantity of 
formazan present in the cell lysate was determined by measuring its absorbance at 
550nm using the Spectrofluoro Plus spectrophotometer (TECAN, GmbH, Grödig, 
Austria). 
2.8 Colony Forming Assays 
MCF-7 (1.5 X 10
5
cells/well), MDA-MB231 (1.5 X 10
5
 cells/well) and T47D 
(1.25 X 10
5
 cells/well) were plated in 12-well plates. Experiments were set up as 
described previously. MCF-7, MDA-MB231 and T47D cells were treated with 
various concentrations of 15d-PGJ2 for 16h. As overnight treatment with 15d-
PGJ2 had effects on cell proliferation, cell numbers were adjusted accordingly to 
take this into account when cells were plated. Colony forming assay was 
performed using 100mm tissue culture dish. Fifteen thousands of treated cells 
were replated onto 100mm dish in RPMI supplemented with 10% fetal bovine 
serum (FBS), 2mM L-glutamine and 0.05mg/ml gentamicin. The cells were then 
allowed to grow for 10 to 15 days and supplemented with complete medium from 




2.9 Luciferase Assays 
MCF-7 (1.25 X 10
5
cells/well), MDA-MB231 (1.25 X 10
5
 cells/well) and T47D 
(1.0 X 10
5
 cells/well) were plated in 12-well plates. Experiments were set up as 
described previously. Cells were seeded for 48h prior to transfection. The cells 
were then transfected with 3XPPRE-TK/Luc construct together with Renilla 
plasmid via calcium phosphate transfection kit. Renilla transfection was used to 
check for transfection efficiency. The luciferase reporter construct used was 
pPPRE-tk-Luc, which contains three PPREs from rat acyl-CoA oxidase promoter 
under the control of the Herpes simplex virus thymidine kinase promoter. It is a 
kind gift from Dr. Ronald M. Evans, The Salk Institute for Biological Studies, 
San Diego, CA, USA. The Renilla control vector (pRL-TK) was purchased from 
Promege. At the end of treatment, 3XPPRE promoter activity was assessed with a 
dual-luciferase assay kit (Promega). Briefly, feeding medium was removed from 
the wells, washed once with 1x PBS, and lysed with ice-cold 100µl of reporter 
lysis buffer. Ten microlitres of cell lysate was then added to 50µl of luciferase 
substrate solution, following which 50µl of stop & glow buffer was added for 
Renilla reading. Bioluminescence generated was measured using a Sirius 
luminometer (Berthold). The luminescence readings obtained were normalized to 
the protein content of the corresponding cell lysate.  
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2.10 Reporter Plasmid Constructs for Chloramphenicol 
acetyltransferase (CAT) Assays 
Chloramphenicol acetyltransferase (CAT) pUCSS-CAT reporter plasmid 
constructs: -1374/+16, -850/+16, and empty vector pUCSS-CAT were kindly 
provided by Dr. Alexey Kolyada, Dept of Medicine, Tufts University School of 
Medicine, Boston, USA (Kolyada et al., 1994).  
2.11 Chloramphenicol Acetyl Transferase (CAT) Assays 
Sodium Hydrogen Exchanger-1 promoter activity was assessed using an enzyme 
immunoassay to determine the expression of the CAT. Cells were grown as 
described previously. Cells were seeded in 12 well plates (NUNC) for 48h prior 
to transfection. Cells were transiently transfected with full length (-1374/+16, 
contains PPRE region) human NHE1 promoter and a 5’ deletion construct lacking 
PPRE region (-850/+16) of the human NHE1 promoter. Cells were treated with 
varying doses of 15d-PGJ2 for 24h. Following that, promoter activity was 
analyzed by CAT ELISA assay (Roche) as described previously (Gorman et al., 
1982). The levels of CAT protein were quantified using a CAT antigen capture 
enzyme-linked immunosorbent assay (ELISA) (Roche Molecular Biochemicals). 
All CAT quantifications were normalized to the protein concentration of the cell 





2.12 Protein Concentration Determination 
Protein determination of cell lysates was carried out using the Coomassie Dye 
(PIERCE, IL, USA) in a 96-well format. One microlitre of cell lysate was added 
to 200µl of Coomassie Dye and its absorbance at 595nm was read using a 
Spectrofluoro Plus spectrophotometer (TECAN, GmbH, Grödig, Austria). The 
Coomassie Plus Protein Assay is based on an absorbance shift from 465nm to 
595nm that occurs when the reagent binds to proteins in an acidic solution. The 
mechanism of the reaction is the anionic form of the dye complexes with proteins, 
resulting in a color change from brown to blue. The dye interacts chiefly with 
arginine residues and weakly with histidine, lysine, tyrosine, tryptophan and 
phenylalanine residues. The reaction reaches a stable endpoint so absorbance 
does not shift over time. Protein standards were prepared using bovine serum 
albumin (PIERCE, IL, USA). 
2.13 Western Blot Analysis 
 
At the end of drug treatment, medium was removed from the wells and the cells 
were washed once with 1x PBS. The cells were re-suspended with 1 x PBS and 
pelleted down by centrifugation at 12000rpm. The cell pellet was completely 
lysed with RIPA lysis buffer (50mM Tris at pH 7.5, 150mM NaCl, 1% v/v NP-
40, 1% v/v deoxycholic acid, 0.1% v/v SDS and 1mM EDTA) containing 1mM 
PMSF, leupeptin, pepstatin A and aprotinin which serve as protease inhibitors; 
1mM of Na3VO4 was added to certain samples as tyrosine phosphatase inhibitors. 
NP-40 in RIPA lysis buffer serves as detergent used to solubilize the lipid in the 
cell membrane and other lipoproteins in the tissue. Deoxycholic acid also serves 
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as detergent to solubilise fats. Sodium dodecyl sulphate (SDS) imposes a negative 
charge on solubilised proteins, thus aiding in protein migration during 
electrophoresis. For detection of NHE1 protein expressions, 80µg of total protein 
per sample was incubated at 37
o
C (to prevent coagulation of membrane-bound 
NHE1) for 5 minutes before being subjected to SDS-PAGE (Polyacrylamide Gel 
Electrophoresis) with 8% (v/v) acrylamide resolving gel at 80V for 20mins 
followed by 100V for 1h using the Bio-Rad Mini-PROTEAN 3 Cell (CA, USA). 
Kaleidoscope prestained standards (Bio-Rad, CA, USA) and biotinyated protein 
markers (Cell Signaling Technology, MA, USA) were also subjected to SDS-
PAGE to facilitate the estimation of the molecular sizes of the protein bands 
obtained. The resolved proteins were then transferred onto a nitrocellulose 
transfer membrane by the wet transfer method at 380mA for 1h using the Bio-
Rad Mini Trans-Blot Electrophoretic Transfer Cell (CA, USA). After the transfer, 
the membrane was then blocked with 5% (w/v) fat-free milk in Tris-buffered 
saline / 0.1% (v/v) Tween 20 (TBST) for 1h. Tween 20 is a mild detergent that 
reduces non-specific binding of antibody to lipid and protein. After three washes 
with TBST to remove excess milk, the membrane was probed for NHE1 with a 
1:1000 dilution of mouse anti-porcine NHE1 monoclonal antibody (Chemicon 
International Inc., Temecula, CA, USA) in 5%  BSA (Bovine Serum Albumin) in 
TBST at 4
o
C overnight. The anti-porcine NHE1 antibody cross reacts with all 
vertebrate NHE1. The membrane was also probed for β-actin using a 1:8000 
dilution of mouse anti-β-actin monoclonal antibody (Sigma, LO, USA) in 5% 
BSA (Sigma, LO, USA) in TBST at 4
o
C overnight. After three washes with 
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TBST to remove unbound primary antibody, the membrane was exposed to 
1:10000 dilution of HRP-conjugated anti-biotin antibody (for biotinylated protein 
markers) together with 1:1000 dilution (for NHE1), or 1:3000 dilution (for β-
actin) of goat anti-mouse IgG-HRP conjugate (PIERCE, Rockford, IL, USA) in 
1% (w/v) fat-free milk in TBST for one hour at room temperature. The probed 
proteins were then detected with Kodak Biomax MR X-ray film by enhanced 
chemiluminescent using the SuperSignal Chemiluminescent Substrate (PIERCE, 
IL, USA). The bands obtained were scanned in with the Amersham Biosciences 
ImageScanner. 
2.14 mRNA Extraction, Reverse Transcription-Polymerase Chain 
Reaction (RT-PCR) and Real Time Polymerase Chain Reaction 
RNA was extracted using trizol. At the end of drug treatment, cell culture media 
was removed from 6-well cell culture plate. Two-hundred and fifty microlitre of 
trizol was added into each well and cells were scrapped in trizol and transferred to 
1.7ml eppendorf tubes. The homogenates were then stored for 5 minutes at room 
temperature to permit complete dissociation of nucleoprotein complexes. The 
homogenates were then supplemented with 0.2ml of chloroform per 0.5ml of 
trizol reagent. The samples were then vortexed and centrifuged at 13000rpm for 
15mins. Following centrifugation, the mixture separates into a lower red phenol-
chloroform phase, interphase and the colourless upper aqueous phase. RNA 
remains exclusivedly in the aqueous phase whereas DNA and proteins are in the 
interphase and organic phase. The top aqueous layer was then transferred into 
fresh tube. RNA was then precipitated by adding equal volume of isopropanol to 
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the samples and mixed thoroughly. The samples were then centrifuged at 
13000rpm for 15mins to precipitate the RNA. Precipitated RNA will form gel-
like/white pellet on the side and bottom of the tube. The supernatant was then 
discarded and the pellet was washed with 80% ethanol. The samples were then 
centrifuged at 13000rpm for another 15mins. Supernatant was then removed and 
RNA pellet was air dried. The RNA was then dissolved in 15ul of 0.1% DEPC 
water. RNA was then quantitated at 260/280nm. Reverse transcription (RT) was 
then carried out. Each RT reaction contains 1ug of total RNA, 1XRT buffer, 
5mM MgCl2, 425uM each of dNTPs, 2uM random hexamers, 0.35U/ul RNase 
inhibitor, 1.1U/ul MultiScribe
TM 
reverse transcriptase and made up to 10ul with 
sterile water. RT reaction was carried out in PCR thermal cycler (Mastercycler 
gradient, eppendorf) at 25
0
C for 10 minutes, followed by 37
0
C for 60 minutes and 
a terminating step at 95
0
C for 5minues. A negative control for RT in which sterile 
water replaced the RNA template was included. Five microlitres of the 10µl 
cDNA reaction volume was used in realtime quantitative PCR using ABI PRISM 
7500 (Applied Biosystems). Normalization was to glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH). Fluorescence was measured with the Sequence 
Detection Systems 2.0 software. PCR was performed in multiplex (both target 
and endogenous control co-amplified in the same reaction) with distinct 
fluorescent dyes. Primers and probe for human glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), human PPARγ, and human NHE1 were purchased as 
kits from Applied Biosystems (Assays on Demand). 
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2.15 Meaurement of Reactive Oxygen Species (ROS) 
Generation of ROS was assessed by using the oxidation-sensitive fluorescent 
probe dichlorodihydrofluorescein diacetate (DCFH-DA) at 5uM, which is rapidly 
oxidized by ROS into its fluorescent derivative. Medium was aspirated from the 
wells and the cells were washed once with 1 x PBS. Two hundred microlitres of 
trypin was added into each well followed by 600µl of serum free media for 
trypsinization. The cell suspension was then transferred to 1.5ml eppendorf tube 
(Axygen Scientific, CA, USA) and pellet at 12000rpm for 5 minutes at 22
0
C. 
Meanwhile, DCFDA was reconstituted in DMSO to give a stock solution of 5mM 
and stored at 4
0
C. After centrifugation, the supernatant was removed and the 
pellet was resuspended in 200µl of serum free media containing 5µM DCFH-DA. 
The cell suspensions were then incubated for 15 minutes in tissue culture 
incubator at 37
0
C. After incubation, the cells were again pelleted at 2000rpm for 
two minutes at 4
0
C. Supernatant was removed and the pellet was washed with ice 
cold 1 x PBS. Cells were then pelleted at 2000rpm for 2 minutes at 4
0
C, 
supernatant was aspirated, and pellet was resuspended with 500µl of room 
temperature 1 x PBS. The cell suspension was then filtered via 60µm filter paper 
and the fluorescent dye was read at excitation λ of 495nm and emission λ of 
525nm on a FACScan flow cytometry. 
Laser scanning cytometry (LSC) was also used for assessing ROS production in 
cells. For LSC method, 7000 cells were seeded in 96 well plates for 48h to allow 
attachment of cells to the plate. The cells were then deprived and treated 
accordingly. At the end of treatment, an equal volume of 5µM CM-H2DCFDA 
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was added to existing media of treated cells to achieve a final concentration of 
2.5µM, then incubated in the dark for 15min at 37
ο
C before aspiration of dye and 
media and replacing with 1 X PBS. The fluorescent dye was read at excitation λ 
of 495nm and emission λ of 525nm on a laser scanning cytometry. 
2.16 Cell Cycle Analysis 
Cell cycle was analysed using propidium iodide staining. Propidium iodide (PI) 
intercalates into double-stranded nucleic acids and produces a highly fluorescent 
adduct that can be excited at 488nm with a broad emission centred around 
600nm. It is excluded by viable cells but can penetrate cell membranes of dying 
or dead cells. Since PI can also bind to double-stranded RNA, it is necessary to 
treat the cells with RNase for optimal DNA resolution. Cells were scraped off the 
wells and subsequently pelleted down by centrifugation at 2500rpm at 4
0
C for 
five minutes. The cells were then washed twice with ice-cold 1% (v/v) FBS in 
PBS before being fixed with 70% (v/v) ethanol to the cell suspension and left to 
incubate for at least 30 minutes at 4
o
C. The fixed cells were then pelleted by 
centrifugation at 10000rpm for five minutes at 4
o
C. The cell pellet was washed 
twice with ice-cold 1% (v/v) FBS in PBS before being stained with 0.5ml of PI / 
RNaseA staining solution for 30 minutes at 37
o
C. The staining solution contains 
10µg/ml PI and 250µg/ml RNaseA dissolved in PBS with 1% FBS. The stained 
cells were then filtered through a 41µm pore size filter before being analysed for 
DNA content using the Coulter Epics Elite ESP Flow Cytometer (FL, USA). At 
least 10,000 events were analysed with the excitation set at 488nm and emission 
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at 610nm. Flow cytometry data was then analysed using WinMDI Version 2.8 
software (http://facs.scripps.edu/).  
2.17 Immunostaining (Immunofluorescence) 
Approximately ~0.05 x 10
6
 cells/ml was seeded on each coverslip of a 12-well 
plate in order to attain ~30% confluence at the time of treatment. After the 
designated duration of treatment, medium was aspirated and the coverslips were 
washed with 1 x cold PBS to rinse the cells. Cells were then fixed with 4% 
paraformaldehyde for 30mins at room temperature. Excess paraformaldehyde was 
washed (rock/shake) with 1 x PBS for two times, 5 mins each. The cells were 
then rock/shake with 1 x cold PBS/100mM NH4Cl for 5 mins twice. It was then 
rinsed with 1x cold PBS before permeabilized with 0.2% TX-100 (Sigma, USA) 
for 10 mins at room temperature. TX-100 was then washed away and the cells 
were incubated with primary antibody, PPARγ (Santa Cruz Biotechnology, USA) 
at 1:100 dilutions, for 1 hour (up to 2 hours) at room temperature. Excess primary 
antibody was then washed away with 1 x cold PBS for 5mins 3 times. Cells were 
then incubated with secondary antibody (1: 200) conjugated to fluorophore for 
45mins to one hour before washing and mounted on FluorSave (Calbiochem, 
USA). The fluorescence can be viewed with fluorescence or confocal microscopy 
(Olympus Fluoview 500). 
2.18 Immunohistochemistry 
 
For PPARγ and NHE1 immunostaining, paraffin wax-embedded sections (4µm) 
were dewaxed in xylene and rehydrated through graduated ethanol to water. 
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Antigen retrieval was performed by microwaving section in Dako citrate buffer, 
pH6.1 for 30minutes. The section was then washed with PBS for 2-3 times. 
Endogenous peroxidase was blocked by incubation for 30 mins in a solution of 
3% hydrogen peroxide. The section was incubated with PPARγ monoclonal 
antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or NHE1 
monoclonal antibody (BD Biosciences Pharmigen) at a dilution of 1:100. It was 
then developed using the Santa Cruz ABC mouse staining system. For substitute 
negative controls the primary antibody was replaced with Tris-buffered saline 
alone. It was then counterstain with Gill’s Hematoxylin for 1.5 minutes. The 
sections were then dehydrate and mount with permanent mounting media.  
2.19 Chromatin Immunoprecipitation Assays (ChIP) 
MCF-7 cells were grown in 100mm dishes to 50-60% confluency prior to 
depriving in serum free medium for 24h, the cells were then treated with 3µM 
and 5uM of 15d-PGJ2 for 6h. Thereafter, cells were washed twice with PBS and 
cross-linked with 1% formaldehyde for 10 mins at room temperature. Next, 
fixation was stopped by adding glycine stop-fix solution and wash twice with 
PBS at 4
0
C. The cells were then collected and resuspended in 1ml ice-cold lysis 
buffer (supplemented with 5µl PIC + 5µl PMSF), and left on ice for 30mins. 
Next, cells were dounced on ice with 10 strokes using a homogenizer and 
collected by centrifugation at 4
0
C for 10mins at 5000rpm to pellet the nuclei. The 
nuclei pellet was then resuspended in 1ml digestion buffer prior to addition of 
50µl of enzymatic shearing cocktail (200 U/ml) and incubate at 37
0
C for 15mins. 





10mins. The chromatin was precleared by addition of protein G beads, ChIP 
buffer and protease inhibitor cocktails (PIC) and rotate at 4
0
C for 1h. The 
precleared chromatin was immunoprecipitated with anti-PPARγ, negative control 
IgG, and RNA pol II antibody and incubated overnight on a rotator at 4
0
C. Next, 
protein G beads were added and precipitation was further continued for 1.5h at 
4
0
C. After pelleting, precipitates were washed sequentially for 1-3mins with 
various wash buffers. The immunocomplexes were then eluted with ChIP elution 
buffer (1% SDS, 0.1M NaHCO3). The eluates were reverse cross-linked by 
heating at 65
0
C overnight and digested with proteinase K at 42
0
C for 2h. The 
purified DNA from the immunoprecipitated complexes of antibody-protein-DNA 
were then detected by PCR (30 cycles) using the specific primer pair spanning the 
NHE1 promoter region containing NHE1-HRE: forward, 5’-GTTGTGGC 
TTACCCCTGTAATCCC-3’; reverse, 5’-GTTTCACCATGTTGGTCAGGCTG-
3’. The PCR products were resolved by electrophoresis in a 2% agarose gel and 
visualized after ethidium bromide staining 
2.20 LightShift Chemiluminescent Electrophoretic Mobility Shift 
Assays (EMSA) 
The EMSA technique is based on the observation that protein: DNA complexes 
migrate more slowly than free DNA molecules when subjected to non-denaturing 
polyacrylamide or agarose gel electrophoresis. Nuclear protein extracts were 
prepared using NE-PER
®
 Nuclear and Cytoplasmic Extraction Reagents 
(PIERCE) according to the manufacturer’s instructions. To study the binding of 
nuclear hormone receptors to the putative PPRE, 26-bp EMSA probe was used: 
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HuNHE1-PPRE-sense (5’-CAC CTG AGG TCA GGA GTT CGA GAC CA-
Biotin-3’); HuNHE1-PPRE-antisense (5’-TGG TCT CGA ACT CCT GAC CTC 
AGG TG-Biotin-3’). Competitor oligonucleotides were the same sense and 
antisense sequences as above without the 3’-biotin label. The 26-bp probe and 
competitor DNA consists of complementary DNA fragments annealed by heating 
to 94°C and slowly cooling to room temperature. A 20µl reaction containing 
10fmol of PPRE probe and 5µg of nuclear extract was incubated with or without 
2µg PPARγ antibody (E8 and H100, Santa Cruz)  for 15mins at room temperature 
in a buffer containing 2.5% glycerol, 5mM MgCl2, 50ng/µl Poly (dI·dC), and 
0.05% NP-40. The DNA-protein complexes were then resolved from the free 
probe by electrophoresis at 4
0
C on a 5% polyacrylamide gel in 0.5 X TBE buffer. 
Double stranded oligonucleotides that were not biotinylated were used for 
competition analysis. It was added at 4pmol final. The samples were then 
transferred to a nylon membrane. The biotin end-labeled DNA is detected using 
the Streptavidin-Horseradish Peroxidase Conjugate and the Chemiluminescent 









3.1 Tumor Breast Tissues Show Higher Expression Of PPARγ 
And NHE1 
Various reports have shown that PPARγ is highly expressed in tumor cells 
compared to normal epithelial cells, including breast, colon, stomach, prostate, 
pancreas, bladder, placenta, lung, chondrosarcoma, and in leukemias. Tumor 
breast epithelium, in particular, was found to express PPARγ in amounts greater 
than those found in normal breast epithelium, independently of their estrogen 
receptor (ER), p53 and HER2/neu status (Elstner et al., 1998; Kilgore et al., 1997; 
Mueller et al., 1998a). HER2 is a protein that is implicated in drug resistance in 
breast cancer patient. In addition, mammary tumors developed much faster in 
offspring of transgenic mice expressing a constitutively active form of PPARγ in 
breast tissue bred to transgenic animals prone to breast cancer (Saez et al., 2004). 
PPARγ was thus suggested to be a novel therapeutic target for breast cancer.  
In spite of this, comparative studies of PPARγ expression in breast carcinoma 
patients so far produced contradictory results. One of the studies conducted 
showed that breast cancer tissues have a lower level of PPARγ transcript 
compared to normal tissues (Jiang et al., 2003). The same study also reported that 
MDA-MB231, an invasive breast cancer cell, exhibited lower level of PPARγ 
expression, compared to non-invasive MCF7. The results of these studies have 
obviously triggered lots of controversies in terms of the effects and applications 
of PPARγ in treatment of breast cancer. 
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In the present study, we wanted to investigate and validate the relevance and 
importance of PPARγ in breast cancer. To this end, we first investigated the 
relative expression of PPARγ in patient samples. Immunohistochemistry 
expression of PPARγ in normal and tumor breast tissues was performed. We also 
looked into expression of NHE1 in serial section of these tissues. This is because 
high levels of NHE1 expression has been implicated in cell proliferation and 
transformation (Putney et al., 2002). The importance of NHE1 is also supported 
by the observation that PPARγ agonist, troglitazone, was shown to induce cellular 
acidosis via inhibition of NHE1 activity (Turturro et al., 2004).  
Interestingly, serial sections of tumor breast tissues showed abundant expression 
of PPARγ and NHE1 compared to normal breast tissues (Figure 5A, B). 
Microscopic analysis showed that PPARγ expression is primarily cytoplasmic in 
both normal and tumor breast tissues. This suggests that these nuclear receptors 
are probably not activated despite its high expression. On the other hand, 
immunohistochemistry and microscopic analysis showed that NHE1, being a 
plasma membrane protein, has a membrane locale, in both normal and tumor 
breast tissues. Coincidently, higher immunoreactivity of NHE1 protein was 
observed in tumor breast tissues (Figure 5A, B). Hence, correlative evidence from 
breast tissues showed that higher PPARγ expression in the cytoplasm is 


























































Figure 5: Expression of PPARγ and NHE1 in normal and tumor breast 
tissues 
Immunhistochemical localization of PPARγ and NHE1 antigens performed on 
formalin-fixed, paraffin-embedded (A) normal and (B) tumor breast tissue. Serial 
tissue sections were deparaffinized, antigen retrieved, and endogenous peroxidase 
B Breast, Tumor 
57 
 
activity was blocked. Tissue sections were incubated with either mouse 
monoclonal PPARγ or mouse monoclonal NHE1 antibodies. Detection was 
carried out using the Mouse ABC Staining System and the tissue sections were 






















3.2 Basal/Relative Abundance Of PPARγ And NHE1 Expression 
In MDA-MB231, MCF-7 And T47D 
After screening for PPARγ and NHE1 expression in tissue samples, we next 
screened for basal PPARγ mRNA expression in three different breast cancer cell 
lines: MDA-MB231, MCF-7 and T47D. Screening was performed to scrutinize 
the relative cellular expression of PPARγ in cancer cell lines that have different 
properties. MCF-7 and T47D are estrogen responsive (ER) cell lines whereas 
MDA-MB231 cell line does not have estrogen receptor (ER negative/resistant cell 
line). Apart from having different levels of PPARγ, these cell lines have different 
ERα, Bcl-2, p53 and BRCA-1 status. The biological profile of these cell lines was 
stated in Table 1 .  
Amongst the three cell lines, PPARγ was found to be most abundantly expressed 
in MDA-MB231 cells, which were shown to be highly tumorigenic and 
metastatic in mouse models; while T47D express the lowest and MCF7 cells 
showed intermediate PPARγ expression (Figure 6A). These three cell lines were 
then chosen for subsequent analysis in order for us to explore the relevance of 
PPARγ expression in breast cancer tumorigenicity and the responsiveness of 
breast cancer cells to PPARγ agonists treatment. Interestingly, we observe a 
possible inverse correlation between PPARγ and NHE1 in terms of protein 
expression in these three cancer cell lines (Figure 6A). To investigate if cells with 
higher expression of PPARγ downregulate basal mRNA expression of NHE1, we 
determined basal mRNA expression of both PPARγ and NHE1 in all three breast 
cancer cell lines by realtime PCR. A much clearer inverse correlation is now 
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observed comparing basal mRNA expression of PPARγ to basal mRNA 
expression of NHE1 in all three breast cancer cell lines. It is interesting to note 
that MDA-MB231 cells, with the highest level of basal PPARγ mRNA, have the 
lowest level of basal NHE mRNA. In converse, MCF-7 cells with the lowest level 
of basal PPARγ mRNA have the highest level of basal NHE1 mRNA (Figure 6B, 
C). This observation leads us to speculate that perhaps PPARγ acts as a repressor 





















Table 1:  Biological profile of MCF
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Figure 6: Relative expression of PPARγ and NHE
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3.3 Presence of Potential PPRE (Peroxisome Proliferator 
Response Element) within Alu Element in the NHE1 Promoter 
Region 
As a first step to determining the potential regulation of NHE1 gene expression, 
we examined the 5’-proximal promoter region of NHE1 for a potential 
Peroxisome Proliferator Response Element (PPRE). DNA sequence analysis 
identified a putative PPRE in the human NHE1 promoter region within an Alu 
element located at nucleotide (nt) –977 to –990 with respect to the TATA box 
(Accession number: L25272) (Figure 7A). This PPRE site is in a primate-specific 
Alu element (Sq) (Jurka and Milosavljevic, 1991), within a cluster of four 
hexamers half-sites recognized by various nuclear receptors (Piedrafita et al., 
1996; Vansant and Reynolds, 1995), termed as Alu receptor response element 
(AluRRE).  
Besides, the putative NHE1 PPRE sequence is highly similar to the consensus 
PPRE for known PPAR target gene except that it has DR2 (direct repeats 
separated by 2 nucleotides) instead of DR1 that is commonly found in consensus 
PPRE (Table 2). Alignment of AluRRE of the human NHE1 with that of human 
myeloperoxidase (MPO) gene shows considerable sequence identity (Figure 7B). 
Similar to NHE1, the PPRE element in MPO is located within an Alu element in 
the promoter region, and the PPRE consists of DR2 instead of DR1 (Kumar et al., 
2004). It was reported that the human MPO gene is regulated by PPARγ via 
estrogen dependent mechanism. Although PPARγ usually binds to direct repeat 
hexamers with 1-bp spacing (DR1), binding by PPARγ to direct repeat hexamers 
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with 2-bp spacing (DR2), though not optimal, has also been reported in the case 
of myeloperoxidase gene. High PPRE sequence similarity between MPO and 
NHE1 suggests that PPARγ may be able to bind to promoter region of the NHE1 
gene which contains DR2 repeats, and subsequently regulates its expressions in a 




























                                                                                                                                 
 
Legends: 
DR : Direct Repeats

























Figure 7: Sequence Analysis of NHE1 Promoter  
(A) Sequence of promoter region of human NHE1 gene was obtained from NCBI 
(Accession # L25272). Bold denotes Alu element (Alusq) where as TATA signal 
denotes start of gene. The underlined sequences are four hexamer repeats that are 
present in AluRRE. (B) The AluRRE of NHE1 gene is aligned to that found in 
myeloperoxidase (MPO) (Kumar et al., 2004) to show the presence of the same 
cluster of four hexamers. These hexamers are organized as direct repeats with 
spacing of 2-4-2 base pairs for both genes. Examinations of 5’ proximal promoter 
region of the human NHE1 gene identified an AluRRE which contains a putative 
PPRE. Sequence analysis also predicted a putative ER binding site close to the 
predicted putative PPRE. These binding sites are highly similar to AluRRE found 
in promoter region of MPO gene where PPARγ agonists strongly bind and 








Table 2: Identified PPRE Sequences (Adapted from Brigitte I. Frohnert, 













3.4 Identification Of A Functional Peroxisome Proliferator 
Response Element (PPRE) In The Promoter Region Of Human 
Sodium Hydrogen Exchanger 1 (NHE1) Gene 
Based upon the sequence of the NHE1 gene upstream region, a putative 
peroxisome proliferator-activated receptor response element (PPRE) is present 
from nucleotide (nt) –977 to –990 with respect to the TATA box. To determine 
whether the NHE1 PPRE was functional and responsive to lipid activators, MDA-
MB231, MCF-7 and T47D cells were transiently transfected with a luciferase 
reporter under the control of three copies of a PPRE using the TK minimal 
promoter. As a control for cell numbers and transfection efficiency, cells were co-
transfected with Renilla vector under constitutive regulation of the HSV-TK 
promoter.  
Sixteen hours after transfection, cells were recovered and deprived prior to 
measurement of PPRE reporter activity. Surprisingly, it was observed that PPRE 
reporter was activated in all three cell lines, even prior to any PPARγ ligands 
treatment. This indicates presence of basal activated PPARγ proteins in cells even 
before treatment with PPARγ ligands. Besides, basal activated PPARγ level was 
observed to be rather similar in all three cell lines tested, despite the differences 
in basal PPARγ expression (Figure 8A).  
Because loss-of-function mutants of PPARγ have been identified in colon cancer 
(Sarraf et al., 1999), we need to show if PPARγ is functional in the three breast 
cancer cell lines. MCF-7, MDA-MB231, and T47D cells were transfected with a 





-prostglandin J2). It was observed that PPRE-luc reporter was 
activated significantly in all three cell lines upon treatment with 15d-PGJ2 for 24h 
(Figure 8B). This showed that 15d-PGJ2 is able to stimulate PPRE-luc reporter 
activity in breast cancer cell lines. In other words, PPARγ in these cells are 
functional and are responsive to PPARγ agonists stimulation. Interestingly, 
stimulated reporter activity in these cell lines correlates with their basal PPARγ 
protein expression. MDA-MB231 cells, with the highest PPARγ protein, 
displayed the highest PPARγ activity while T47D cells, with the lowest PPARγ 
protein, had the lowest PPARγ activity. MCF7 cells had intermediate levels of 
PPARγ expression and hence PPARγ activity (Figure 8B). Thus, we conclude 
that 15d-PGJ2 induced higher PPRE reporter activity in cell lines that express 
higher PPARγ. These experiments showed the ability of 15d-PGJ2 to transactivate 


























Figure 8: PPRE reporter activity in three breast cancer cell lines, MDA
MB231, MCF-7 and T47D
MDA-MB-231, MCF-7, a
dishes as described in Materials and Methods (M&M). 
cells were transiently transfected with a 3XPPRE
a plasmid encoding for the 
measured (B) Cells were 





nd T47D cells were seeded at 1.25 X 10
5
 cells/12
Forty-eight hours later, 
-luc reporter gene construct and 
Renilla protein. (A) PPRE reporter activity was 
treated with 3µM 15d-PGJ2 for 24h 







RLU/renilla/µg total protein and expressed as percentage increase of the promoter 
activity relative to cells maintained in medium without 15d-PGJ2 (untreated). 




















3.5 Regular Serum Versus Charcoal Stripped Serum Condition 
Used In Experiments 
It has long been established that charcoal treatment of serum is effective in 
removing steroids and has been used in numerous studies both in vivo and in 
vitro (Darbre et al., 1983). To achieve this, high quality FBS is processed using a 
proprietary charcoal/dextran to reduce the levels of many hormones and growth 
factors. The serum is then filtered through three sequential 100nm (0.1µm) pore-
size rated filters. Charcoal/Dextran FBS has been established to be effective in 
reducing steroid levels for utilization in receptor studies or estrogen related 
investigations. Besides, Murate et al. have also shown in their human marrow-cell 
system that they are able to minimize lot-to-lot serum variability by treatment 
with charcoal/dextran (Murate et al., 1988). This is to ensure consistency in 
experiments where serum is being utilized. Table 3 shows the component assays 
comparison between charcoal/dextran FBS versus control/nontreated FBS. It is 
noteworthy that charcoal/dextran treatment significantly reduces 17β-estradiol 
and prostaglandin levels in FBS. For 17β-estradiol, the level was reduced from 
8.5pg/ml to 5pg/ml whereas the level for prostaglandin was reduced by more than 
50%. This is in particular very important in our system because presence of high 
levels of estradiol and prostaglandin in FBS could lead to constitutive activation 
of ERα and PPARγ, and this might mask the effects of drug treatment. Estradiol 
and prostaglandins are activators for ERα and PPARγ respectively. In our system, 
basal PPARγ activation is in particular very important because our research 
focuses on the induced activation of PPARγ by its  ligand. Besides, PPARγ being 
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a nuclear receptor, is also activated by various steroid components that are 
present in the serum. Hence, reduction of these components is actually important 
in keeping basal PPARγ activation in the system to be minimal and consistent.  
On the other hand, phenol red in tissue culture media has also shown to be a weak 
estrogen (Berthois et al., 1986). In the five media used most commonly for human 
breast cancer cells, phenol red concentrations is: 10mg/liter (30µM) for Eagle’s 
MEM, Improved MEM, and Leibovitz L-15 media; 5mg/liter (15µM) for RPMI 
1640 mdium; or 15mg/liter (45µM) for Dulbecco’s MEM. Thus, MCF-7, MDA-
MB231 and T47D cells grown in phenol-red containing medium under apparently 
“control” conditions are, in fact, significantly estrogen-stimulated in terms of 
growth rate and progesterone receptor levels. Furthermore, estrogen receptor was 
previously shown to bind to PPRE region of genes and negatively interferes with 
PPARγ signaling in breast cancer cells (Bonofiglio et al., 2005). Hence, presence 
of phenol red in the media might therefore interfere with the effects of PPARγ 
activation in our system.  
Next, we tested the effects of endogenous PPARγ ligand, 15d-PGJ2, on NHE1 
expression in both regular and charcoal/dextran FBS condition. This step was 
meant to validate the usage of charcoal/dextran FBS in the system and also served 
as initial screening in the search for effects of PPARγ activation on NHE1 
expression. Basically, MCF7 cells were seeded/plated in two different 
experimental settings. One set of cells were seeded in RPMI supplemented with 
10% regular FBS while the other set of cells were supplemented with 10% 
charcoal/dextran treated FBS. The cells were then deprived and treated with 15d-
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PGJ2 accordingly in phenol free RPMI. Cells were then harvested for western blot 
analysis. Interestingly, it was observed that PPARγ ligands downregulated NHE1 
protein expression in MCF7 cells in a dose dependent manner in both sets of 
experimental settings. However, the reduction was more prominent in cells 
seeded in RPMI supplemented with 10% charcoal/dextran FBS condition 
compared to the other experimental setting (Figure 9). This suggests that 
components that are present in regular FBS would possibly interfere with PPARγ 
induced downregulation of NHE1. This observation justified the usage of 
charcoal/dextran FBS in experiments involving nuclear receptors, as explained in 
earlier paragraphs. Besides, it was previously shown that mitogenic agonists such 
as insulin, thrombin and epidermal growth factors were also able to increase 
transcription from the NHE1 promoter (Besson et al., 1998). Presence of these 
factors would then probably mask or overpower PPARγ effects on NHE1, if there 
was any. Hence, charcoal/dextran FBS condition was utilized in all subsequent 
experiments in order to scrutinize the actual effects that PPARγ might have on 
NHE1.  
Subsequently, for all experiments, cells were seeded in RPMI supplemented in 
10% charcoal stripped FBS for 48 hours. These cells were then deprived in 
phenol free RPMI 0% serum overnight. Deprivation step was aimed to remove 
the remaining prostaglandins or other components present in the serum that 
would interfere with nuclear receptor activation. The cells were then treated 
accordingly. This setting is applicable to all experiments performed, unless 




Table 3: Component Assay Comparison, Charcoal/Dextran-Treated FBS 







Figure 9: NHE1 expression upon 24hours 15d
versus charcoal stripped serum condition
MCF-7 cells were seeded at 3 
and Methods (M&M). Cells were seed in two different experimental conditions, 
one set in RPMI supplemented with 
(B) RPMI supplemented in 10% charcoal/dextran treated serum. Cells 
allowed to grow for 48h prior to 24h
supplemented with (A) 0.5% regular serum or 
supplementation. Cells were then treated with 15d
extract was analyzed using monoclonal antibodies against human NHE1. β












 cells/6-well dishes as described in Materials 
(A) 10% regular serum while the other set in 
 deprivation in phenol free RPMI 
(B) phenol free RPMI without any 







3.6 Activated PPARγ Translocates From Cytoplasm To Nucleus 
Immunohistochemistry analysis on tumor breast tissue showed that PPARγ is 
primarily located in the cytoplasm. Next, we asked if this is also true in breast 
cancer cell lines. Immunofluorescence staining was performed to detect the 
location and relative abundance of inactivated and activated PPARγ proteins in 
MCF-7 cells. The immunofluorescence micrograph (Figure 10A) showed the 
translocation of PPARγ upon ligand activation (3µM 15d-PGJ2). It was observed 
that PPARγ proteins were mainly located in the cytoplasm of the untreated cells. 
At 4h after treatment, translocation of PPARγ proteins was being detected. The 
green fluorescence dye was seen to mainly concentrate in the nucleus of the cells. 
Hoerchst was used to stain double stranded DNA. It attaches to the minor groove 
of the DNA helix around A-T clusters. The fluorescence can be detected at 
460nm. On the other hand, FITC is conjugated to anti-mouse antibody, which in 
turn binds to mouse anti-PPARγ antibody.  
Next, we wanted to know if synthetic PPARγ ligands, the thiazolidinediones 
(TZD) class of antidiabetic drugs for type II diabetes, were also able to activate 
PPARγ and lead to its translocation. We treated cells with rosiglitazone, a 
synthetic PPARγ ligand that belongs to the TZD class. Similar observations were 
noted (Figure 10B). Hence, we concluded that in the absence of any trigger, most 
PPARγ is inactive. These inactive PPARγ was primarily found in cytoplasm in 
breast cancer tissues as well as breast cancer cell lines. Upon activation by its 
ligands, both endogenous and synthetic, these PPARγ proteins would then 
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translocate from the cytoplasm to the nucleus, where functional transcription 






























Figure 10: PPARγ Translocates From Cytoplasm To Nucleus of Cells 
MCF-7 cells seeded at 5X10
4
/coverslip in a 12-well dish. Cells were then treated 
with (A) 3µM 15d-PGJ2 and (B) 20µM rosiglitazone for 4hrs. Following the 
methodology outlined in M&M, cells were incubated with antibody against 
PPARγ and then with secondary antibody conjugated to fluorophore (middle 
0µM 15d-PGJ2  
3µM 15d-PGJ2  








panel). Nuclear staining with Hoerchst dye (left panel). Merged images shown in 






















3.7 PPARgamma Binds To PPRE Region Within NHE1 Promoter 
Sequence alignment analysis showed that PPRE is present within the Alu 
sequences in the promoter region of NHE1. However, presence of PPRE and 
functional PPARγ in cells do not necessarily imply the physical binding of 
PPARγ to PPRE at promoter region of NHE1. Besides, PPARγ normally binds to 
hexamer repeats with spacing of 1-bp (DR1). In the context of NHE1, the 
hexamer repeats that are present within the Alu sequences contain 2-bp spacing 
(DR2). Thus, having identified this putative PPRE on NHE1 promoter and the 
kinetics of PPARγ activation and translocation to the nucleus upon activation by 
15d-PGJ2, we then investigated whether PPARγ protein targets the NHE1 
promoter in vitro, using a non-radioactive gel shift assay (Pierce).  
Biotinylated double-stranded oligonucleotides containing hexamers 3/4 of the 
NHE1 PPRE site was used as probe, 5’-
CACCTGAGGTCAGGAGTTCGAGACCA-3’. Nuclear extracts were prepared 
from MCF7 and MDA-MB231 cells either untreated or treated with 3µM 15d-
PGJ2 for 6h. As shown in Figure 10A (lane2, lane7) , there is presence of some 
basal PPARγ binding to NHE1 PPRE using nuclear extract from untreated MCF7 
and MDA-MB231 cells. Free probe is shown in Figure 10A (lane1, lane6). 
However, the intensity of this retarded complex increased significantly when 
using nuclear extract from 3µM 15d-PGJ2-treated MCF7 (Figure 10A, lane3) and 
MDA-MB231 cells (Figure 10A, lane8), indicating a ligand-dependent binding of 
PPARγ to NHE1 PPRE. This binding was specific as it could be competed out 
with non-biotinylated NHE1 PPRE oligonucleotides (Figure 10A, lane4, lane9). 
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The presence of PPARγ in the retarded complex was demonstrated by incubating 
the nuclear extract from MCF7 and MDA-MB231 cells treated with 3µM 15d-
PGJ2 with an anti-PPARγ antibody, which blocked complex formation (Figure 
10A, lane5, lane10).  
We further confirmed binding of PPARγ receptor to NHE1 PPRE in vivo, by 
chromatin immunoprecipitation (ChIP) experiments using a ChIP-validated 
antibody to PPARγ (E8 and H100) (Active Motif). As negative control, IgG was 
used in this assay. The presence of the NHE1 promoter, more specifically 100bp 
region spanning the NHE1 PPRE, in chromatin immunoprecipitates was detected 
by semiquantitative PCR. Sequence for the forward primer is 5’-
GTTGTGGCTTACCCCTGTAATCCC-3’ while reverse primer is 5’-
GTTTCACCATGTTGGTCAGGCTG-3’. Sheared chromatin served as input. 
Consistent with our gel shift results, in vivo studies also showed that PPARγ 
binds to NHE1 PPRE in a ligand-dependent manner (Figure 10B). This is due to 
increase amount of NHE1 PPRE being detected in samples supplemented with 
increase doses of PPARγ ligands (0, 3, 5µM 15d-PGJ2). This binding was specific 



















1         2       3         4       5                       6         7        8        9      10
MCF7
MDA-MB231
1, 6: No nuclear extract
2, 7: Nuclear extract (0µM 15d-PGJ2)
3, 8: Nuclear extract (3uM 15d-PGJ2)
4, 9: Nuclear extract (3uM 15d-PGJ2) + Competitive DNA (Nonbiotinylated oligonucleotides)
5, 10: Nuclear extract(3uM 15d-PGJ2) + PPARγ Antibody (E8 + H100)
15d-PGJ2 (µM)           0             3           5            0            3            5   









Figure 11: PPARγ binds to PPRE region within human NHE1 promoter in a 
ligand-dependent manner.  
(A) LightShift Chemiluminiscent EMSA using 5µg nuclear extracts from 
untreated and 3µM 15d-PGJ2 treated for 6h. Free 10fmol biotinylated NHE1 
PPRE doubled stranded oligonucleotides shown in lane 1. Lane 2 show presence 
of a DNA/protein complex (indicated by←) using nuclear extract from untreated 
MCF-7 cells. Lane 3 shows increased DNA/protein complex when using 3µM 
15d-PGJ2 treated MCF-7 cells. Lane 4 shows DNA/protein complex out-
competed by 4pmol non-biotinylated NHE1 PPRE oligonucleotides. Presence of 
PPARγ protein in the DNA/protein complex confirmed using 2µg anti-PPARγ 
antibody, indicated by disappearance of the retarded complex (Lane 5). Lane 6 to 
10 has similar treatments, but in MDA-MB231. (B)Chromatin 
immunoprecipitation (ChIP) assay using nuclear extract from 5.4 X 10
6
 untreated 
and 3µM and 5µM 15d-PGJ2 treated for 6h MCF-7 cells. ChIP assay (Active 
Motif) was performed as outlined in materials and methods (M&M). Sheared 
chromatin was immunoprecipitated using a control rabbit IgG (negative antibody) 
and ChIP-validated PPARγ antibody (anti-PPARγ). Presence of NHE1 PPRE 
containing region (~100bp) in immunoprecipitates is shown in figure after 
semiquantitative PCR and resolved in 2% agarose gel. Sheared chromatin before 





3.8 PPARγ Activation By Natural Ligand, 15d-PGJ2 And 
Synthetic Ligands, Downregulate NHE1 mRNA And Protein 
Levels In Human Breast Cancer Cells 
While PPRE-luciferase assays, ChIP assays and nonradioactive gel shift assays 
demonstrate the ability of PPARγ ligands to activate PPARγ and induces PPARγ 
binding to PPRE at promoter region of NHE1, we wanted to assess the effect of 
exposure of breast cancer cell lines to PPARγ ligands on NHE1 gene expression. 
For this, MCF7, MDA-MB231 and T47D were treated with 3µM and 5µM of 
15d-PGJ2 for 24h. 15d-PGJ2 is an endogenous ligand for PPARγ. Kliewer et al. 
reported that prostaglandin J2 and its derivatives are efficacious activators of 
peroxisome proliferator-activated receptors α and γ. The PGJ2 metabolite 15-
deoxy-12,14-PGJ2 binds directly to PPARγ and promotes efficient differentiation 
of C3H10T1/2 fibroblasts to adipocytes (Lehmann et al., 1995). 
Following treatment with 15d-PGJ2, the change in NHE1 mRNA and protein 
expression were then detected by using real time PCR and also immunoblotting. 
Interestingly, the results showed that  treatment of cells with 1 to 5µM 15d-PGJ2 
caused a dose-dependent decrease in NHE1 expression, at both mRNA and 
protein levels, in all three breast cancer cell lines tested (Figure 12A, B, C). It is 
noteworthy that the endogenous cellular expression of PPARγ correlated with the 
efficiency of 15d-PGJ2 to repress NHE1 expression. The higher the level of 




In addition to endogenous PPARγ ligand, 15d-PGJ2, there are several synthetic 
PPARγ ligands already in clinical use for the treatment of type 2 diabetes. These 
thiazolidinedione (TZD) class of ligands for PPARγ include troglitazone, 
rosiglitazone, and pioglitazone, also known in the clinical setting as Rezulin, 
Avandia and Actos, respectively. Given the widespread incidence of type II 
diabetes and lifelong exposure of these patients to TZDs, there is a possibility that 
chronic treatment with TZD modifies clinical phenotypes of other common 
human diseases, for example breast carcinoma. There is also evidence that TZDs 
could act as breast carcinoma suppression agents, at least in the in vitro and 
animal models.  
To investigate if all ligands of PPARγ, whether endogenously or synthetically 
produced, mediate transrepression of NHE1, MCF7 cells were treated with 
synthetic PPARγ ligands. This is to investigate if the downregulation of NHE1 
expression is drug dependent or PPARγ ligands dependent. Western blot analysis 
showed that these synthetic drugs can indeed downregulate NHE1 expression in 
MCF7 cells in a dose dependent manner (Figure 12D, E, F). This provides 
evidence that the downregulation of NHE1 is not drug specific, but is attributed to 
PPARγ activation.  
Together, these data demonstrate that PPARγ agonists are capable of repressing 
NHE1 expression not only at protein level, but also at the transcriptional level. 
The difference in efficacy on the repression of NHE1 expression between 15d-
PGJ2 and the three synthetic PPARγ ligands may be explained by the difference 
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Figure 12: PPARγ activation downregulates NHE1 mRNA and protein levels 
in human breast cancer cells. 
MCF-7, MDA-MB231, a
as described in Materials and Methods (M&M). 
quantified by Taqman real
NHE1 mRNA expression is expressed as percent of untreated control. NHE1 
protein expression analyzed b









nd T47D cells were seeded at 3 X 10
5
 cells/6-well dishes 
NHE1 mRNA expression was 
-time PCR, normalized to human GAPDH. Relative 
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Cells were then treated with increasing doses of various synthetic ligands of 
PPARγ: (D) ciglitazone, (E) troglitazone, (F) rosiglitazone. NHE1 protein 
expression was then determined by Western blot. Detection of β-actin served as 


















3.9 Normal Breast Epithelial Cells With Low PPARγ Levels Are 
Not Affected by 15d-PGJ2 Treatment 
Elstner et al. have shown that breast cancer cells express high levels of PPARγ, 
whereas normal breast epithelial cells lining the mammary ducts express only a 
low level of this receptor (Elstner et al., 1998). In the present study, we showed 
high expression levels of both PPARγ and NHE1 proteins in tumor breast tissue 
while expression of these proteins is minimal in normal breast tissues. Thus far 
we also showed that expression levels of PPARγ correlated with the efficiency of 
15d-PGJ2 to repress NHE1 expression. If this is true, then normal cells with very 
low levels of PPARγ should not be affected by 15d-PGJ2 at doses used in this 
study. However, there are also some reports that showed otherwise. It was 
reported that instead of having lower expression of PPARγ, normal human 
mammary epithelial cells (HMEC) has higher PPARγ mRNA expression 
compared to MCF7 breast cancer cell line. Treatment of these cells with PPARγ 
selective ligands, 15d-PGJ2 and ciglitazone, were shown to inhibit the growth of 
HMECs in a dose dependent manner (Yee et al., 2003).  
Hence, given the controversy in terms of PPARγ expression in tumor versus 
normal breast cell lines, we first wanted to determine the relative PPARγ 
expression in breast cell lines in our system, both normal and tumor cell lines. 
HTB125 and MCF10 normal breast cell lines were utilized for comparison with 
MCF-7 cells. HTB125 was isolated from normal breast tissue peripheral to an 
infiltrating ductal carcinoma and it has epithelial adherent morphology. MCF10 
cell line, on the other hand, was derived from benign mastectomy tissue. These 
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cells became spontaneously immortalized in culture into a non-tumorigenic, 
putatively normal cell line. Lysates of these cells were collected for western blot 
analysis as stated in materials and methods (M&M). From Figure 13A, it is 
evident that normal cells do indeed have very low basal levels of PPARγ receptor 
as compared to tumor cells. Next, we asked if similar drug concentrations that 
downregulate NHE1 expression in breast cancer cells could elicit the same 
response in normal cells. Coincident with having very low levels of PPARγ 
receptor, exposure of these cells to 15d-PGJ2 up to 5µM does not lead to a 
decrease in NHE1 expression (Figure 13B). Similar results were previously 
observed in T47D breast cancer cell line, which has low PPARγ expression. This 
suggests that up to 5µM of 15d-PGJ2 could downregulate NHE1 expression in 
cancer cell lines that express high level of PPARγ, but not in normal cells or 
cancer cells that express little PPARγ. This was surprising but very interesting 
clinically because now we have a way to selectively decrease NHE1 gene 
expression in breast cancer cells but not normal breast cells. This implies that 
PPARγ could probably be a target that can be used as adjuvant therapy to combat 

















Figure 13: Up To 5µM of 15d
in normal cell lines.  
(A)Normal breast cells MCF10A, HTB125, and breast tum
seeded in 6-well dish in duplicate. Basal NHE1 and PPARγ protein expression 
were then analyzed by Western blot. Detection of β
control. (B) MCF10A and (C)
well dish in duplicate. Cells were then treated with
for 24h. NHE1 expression was 
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3.10 Effects Of PPARγ Agonists on NHE1 Is PPARγ Dependent, 
In Both Normal and Tumor Breast Cell Lines 
The results so far showed that cell lines that have more PPARγ seems to be more 
responsive to PPARγ ligands treatment and vice versa. This is especially obvious 
in normal breast cell lines, both MCF10A and HTB125, where treatment with 
PPARγ ligands did not show any repression of NHE1 expression. These cells 
have very low level of PPARγ, as shown previously in Figure 13A. This leads to 
the speculation that probably PPARγ is responsible for downregulating NHE1 
expression.  
However, PPARγ ligands have also been shown to be able to induce both PPARγ 
dependent and independent effects. For example, 15d-PGJ2 interferes with NFkB-
mediated gene regulation by generating adducts with cysteine residues in NFkB 
and IkB kinase (Powell, 2003). To confirm level of PPARγ expression does 
determine the effects of 15d-PGJ2 on the repression of NHE1 expression, we 
transfected plasmid encoding mouse PPAR (mPPARγ) in MCF10A and HTB125 
cells. Remarkably, overexpression of PPARγ in MCF10A and HTB125 cells 
resulted in a more significant decrease in NHE1 protein expression when 
compared to cells transfected with only the empty vector (Figure 14A, B). 
Furthermore, PPRE reporter activity was also enhanced in HTB125 cells that 
were transfected with mouse PPARγ prior to treatment to 15d-PGJ2, as compared 
to cells that were transfected with empty vector (Figure 14C). Our results 
therefore suggest the inhibitory effects of 15d-PGJ2 on NHE1 expression belongs 
to PPARγ-dependent transrepression. This observation is crucial as it implies that 
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increased PPARγ levels in cells leads to higher PPARγ activity upon activation 
by ligands. Increased PPARγ activity would then enhance repression of NHE1 
expression by PPARγ agonists.  
Our previous data also showed that apart from normal breast cells, T47D also has 
low level of PPARγ. PPARγ agonists were previously shown to be unable to 
induce significant NHE1 repression in T47D breast cancer cell line. Hence, we 
wanted to investigate if PPARγ level does play a role in NHE1 downregulation in 
breast cancer cell lines. For this, T47D and MCF-7 cell lines were selected. 
Similar mouse PPARγ overexpressing experiments were performed. Interestingly, 
similar results were observed in these two breast cancer cell lines. There is 
enhanced NHE1 repression in cells that were transfected with mPPARγ plasmid 
prior to treatment with 15d-PGJ2, as compared to cells that were transfected with 
empty vector alone (Figure 15A, B). Besides, it was observed that there was 
enhanced PPRE reporter activity and NHE1 repression in cells that were 
transfected with mouse PPARγ prior to treatment with 15d-PGJ2, as compared to 



























Figure 14: Effects of 15d
(A) MCF10A and (B) HTB125 cells were transfected with 5µg plasmid encoding 
mouse PPARγ (mPPARγ) as described in Materials and Methods. Control cells 





-PGJ2 in normal cell lines is PPARγ-dependent.  
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following transfection, cells were treated with increasing doses of 15d-PGJ2 for 
24h. NHE1 protein expression was then determined by Western blot. Detection of 
β-actin served as loading control. Overexpression of PPARγ expression from the 
transfected plasmid 48h following transfection is shown at top panel (C) HTB125 
cells were transiently transfected with a 3XPPRE-luc reporter gene construct and 
a plasmid encoding for the Renilla protein. PPRE reporter activity was measured. 
Data were calculated as luciferase RLU/renilla/µg total protein and expressed as 
percentage increase of the promoter activity relative to cells maintained in 
medium without 15d-PGJ2 (untreated). Data represents the average +/-SD of two 


































Figure 15: Effect of 15d
PPARγ overexpression in (A) T47D or (B) MCF7




-PGJ2 in breast cancer cells is PPARγ-dependent. 
 cells increases the inhibitory 





PPARγ activity. T47D or MCF-7 cells transfected with either pCMX-mPPARγ 
(mPPARγ) or empty vector. Cells were then treated with varying doses of 15d-
PGJ2 for 24h. Lysates were then collected for western blot analysis and PPRE 
reporter activity. Data were calculated as luciferase RLU/renilla/µg total protein 
and expressed as percentage increase of the promoter activity relative to cells 
maintained in medium without 15d-PGJ2 (untreated). Data represents the average 















3.11 Pharmacological PPARγ Antagonism Blocks The Effects Of 
PPARγ Ligands On PPRE Reporter Activity And NHE1 Gene 
Expression 
Another means to test whether a given effect is mediated by PPARγ activation is 
by using the PPARγ antagonist, 2-chloro-5-nitrobenzanilide (GW9662). GW9662 
is able to covalently modify cysteine
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 in the ligand binding domain of PPARγ, 
thus preventing its activation by its ligands. This modification was also shown to 
be irreversible. Although GW9662 reacts with all three PPAR subtypes, the 
antagonist activity is at least 100-1000 fold more potent for PPARγ than α or β 
(Leesnitzer et al., 2002); therefore, it is considered a selective PPARγ antagonist.  
In order to test the ability of GW9662 in inhibiting PPARγ activation, MDA-
MB231, MCF7 and T47D cells were transfected with 3XPPRE-luc and pTA-luc 
(control plasmid) together with Renilla plasmid for transfection efficiency 
verification. Cells were then preincubated with GW9662 for 2 hours prior to 
treatment with 15d-PGJ2 for 24h. Later, cells were harvested and checked for 
PPRE reporter activity indirectly via measuring luciferase activity. As expected, 
cells that were treated with 3µM and 5µM of 15d-PGJ2 alone showed drastic 
increase in PPRE reporter activity, in all three breast cancer cell lines tested: 
MDA-MB231, MCF7 and T47D (Figure 16A, B, C). However, preincubation of 
cells with GW9662 prior to 15d-PGJ2 treatment blocked/abrogated PPRE reporter 
activity observed in all three cell lines (Figure 16A, B, C ). This indicates that 
GW9662, being a pharmacological PPARγ antagonist, is indeed functional and 
able to inhibit PPARγ activation, as measured via luciferase activity. Besides, the 
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data also conclusively implies that PPRE region is largely bound and stimulated 




































Figure 16: GW9662 blocks the functional activity of PPARγ
(A) MCF7, (B) MDA-MD
with reporter plasmid 3XPPRE
three cell lines were treated with 3µM 15d
A. MCF7 




-231 and (C) T47D cells were transiently transfected 
-luc. Forty eight hours following transfection, the 
-PGJ2 for 24h with and without 2h 
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preincubation with 15µM GW9662. Cells were harvested for luciferase assay as 
described in Materials and Methods. Data were calculated as luciferase 
RLU/renilla/µg total protein and expressed as percentage increase of the promoter 
activity relative to cells maintained in medium without 15d-PGJ2 (untreated). 

















3.12 The Anti-Tumor Effects Of PPARγ Activation 
Next, we wanted to investigate if PPARγ agonists induced regulation of NHE1 
would be applicable and beneficial to breast cancer patients. Tumor invasion and 
metastasis are the major causes of morbidity and death in breast cancer patients. 
Various studies conducted recently showed that PPARγ ligands were able to 
reduce colony forming ability of cells (Vignati et al., 2006). This would then 
mean reduced metastasis of tumor cells. Hence, we asked if the potential growth-
inhibitory effects of 15d-PGJ2 are relevance in this system and if this is related to 
NHE1 downregulation. For this, MCF-7, MDA-MB231 and T47D cells were 
challenged with PPARγ ligands for 16h. As 15d-PGJ2 had an effect on cell 
proliferation, the cell numbers were adjusted accordingly to take that into 
consideration. The cells were then replated onto 100mm culture plates and 
incubated for 10 to 15 days to allow colonies to form. Similar to results 
previously reported by others (Kubota et al., 1998), endogenous PPARγ agonists 
15d-PGJ2 caused inhibition of breast cancer cell proliferation as shown in colony 
forming assays in our system. A dose-dependent effect was achieved over the 
3µM to 5µM range tested. These levels are similar or lower than those that were 
previously shown to achieve PPARγ-mediated effects in other cell types and 
systems (Huang et al., 1999) and were clearly non toxic to cells, based on flow 
cytometric analysis that we had performed in the later part of our studies. 
Although these cells were serum deprived for a total of 40hours, the results 
showed that serum deprivation has not depleted colony forming ability of these 
breast cancer cells, as control cells were shown to retain colony forming abilities. 
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Inhibition was clearly evident at 3µM and was essentially complete at 5µM for 
MCF-7 and MDA-MB231 cell lines. In addition to fewer colonies, formed 
colonies were discernibly smaller at the higher concentration ranges. However, 
15d-PGJ2 at 3µM did not significantly inhibit the colony-forming ability of T47D 
cells (Figure 17). It is interesting to note here that 15d-PGJ2 at 3µM down-
regulated NHE1 expression in MCF-7 and MDA-MB231 cells but not that in 
T47D cells. At 5µM 15d-PGJ2, the ability of all three breast cancer cell lines to 
form colonies were diminished. Note that 15d-PGJ2 at this concentration inhibited 
NHE1 expression in all three cell lines. These observations seem to suggest that 
expression of NHE1 could be an important determinant in tumor cells’ ability to 
form colonies; downregulation of NHE1 expression would probably be the key 



























Figure 17: PPARgamma agonists reduced colony forming ability of breast 
cancer cells. 
MCF7, MDA-MB231 and T47D cells were seeded as stated in materials and 
methods (M&M). After 24h deprivation, the cells were then triggered with 3µM 
and 5µM 15d-PGJ2 for 16h. Cells were then washed and resuspended in 100mm 
culture dishes at a density of 1.5X10
4
 cells/dish with medium containing RPMI 
supplemented with 10% FBS. During the 10-14 days continued incubation, 
medium was replaced every 3 days. At the end of incubation, cells remaining in 
100mm dishes were stained with crystal violet. Digital images from scanned 











3.13 Reduced NHE1 Expression Is Involved In The Anti-Tumor 
Effects Of PPARγ Activation 
Thus far, our studies showed that PPARγ ligands were able to downregulate 
NHE1 expression, subsequent experiments also showed that PPARγ has growth-
inhibitory effects. Hence, we asked if this growth inhibitory effect of PPARγ is 
due to NHE1 downregulation. A role for NHE1 in cell proliferation was initially 
inferred from the growth-promoting effect thought to be associated with mitogen-
induced increases in pHi. Pouyssegur and colleagues first reported that the 
proliferative rate of mutant fibroblasts lacking NHE activity was markedly 
impaired compared to parental NHE-competent cells at neutral and acidic pH 
(Pouyssegur et al., 1984). This is the first study that implies the importance of 
NHE1 in cell proliferation. Subsequently studies using pharmacological inhibitors 
of NHE1, such as EIPA or HOE694, indicated that NHE1 has a permissive, but 
not an obligatory, role in promoting proliferation in response to mitogens and 
oncogene expression (Delvaux et al., 1990). 
In order to investigate the role of NHE1 in proliferation, we first asked if NHE1 
by itself is able to regulate colony forming ability of cells. To perform this, NHE1 
expression was silenced in both MCF-7 and MDA-MB231 using siRNA specific 
for NHE1 gene, the cells were then replated onto 100mm dish for 10 to 15 days. 
Colony forming ability of these cells was then investigated. Interestingly, 
silencing NHE1 expression reduces colony forming ability of breast cancer cells, 
in both MCF-7 (Figure 18A) and MDA-MB231 (Figure 18B). MCF-7 cells have 
high expression of NHE1 while MDA-MB231 has very low basal expression for 
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this protein. This shows that NHE1 plays significant role in colony forming 
ability of breast cancer cells, regardless of the basal NHE1 expression in these 
cells.  
Next, we wanted to investigate if NHE1 is responsible for PPARγ ligands 
induced reduced colony forming ability of cells. In order to further investigate the 
relevance of NHE1 in PPARγ inhibition of colony forming ability of cells, we 
overexpressed NHE1 using pcmV-NHE1 plasmid in MDA-MB231 cells prior to 
treatment of cells with 3uM 15d-PGJ2 for 16h. The cells were then replated onto 
100mm dishes and allowed to grow for 10 to 15 days. MDA-MB231 cells were 
selected for this experiment because this cell line expresses least basal NHE1 
level compared to all the breast cancer cell lines tested. Hence, using MDA-
MB231 cell lines, we wanted to know if overexpressing NHE1 is able to diminish 
PPARγ ligands induced reduced colony forming ability of cells. Consistent with 
the results that were shown previously, it was observed that 3µM of 15d-PGJ2 
reduces colony forming abilities of cells that were transfected with empty vector. 
Smaller and less colonies were formed. On the other hand, overexpressing pcmV-
NHE1 plasmid in MDA-MB231 diminished 15d-PGJ2 induced decreased colony 
forming ability of breast cancer cells (Figure 18C). This suggests that PPARγ 
reduces colony forming ability of cells via reduction in NHE1 expression. 
Overexpressing NHE1 in these cells render them to be less sensitive to PPARγ 
ligands treatment.  







































Figure 18: Reduced NHE1 expression contributes to anti
PPARγ activation 
Expression of NHE1 was silenced in  (A)
using NHE1 specific siRNA. Forty eight hours following silencing, 1.5X10
were reseeded in 100mm culture dishes for 15days. Digital images from scanned 
plates are shown. Successful 
after 48h of transfection was determined by Western blot, expression of β
serve as loading control. (C) MDA
plasmid encoding NHE1 as described in Materials and Me
were transfected with empty parent vector, pCMV. Forty eight hours following 
transfection, cells were treated with increasing doses of 15d
C 
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-tumor activity of 
 MCF7 and (B) MDA-MB231 cells 
knock-down of NHE1 expression in both cell lines 
-MB231 cells were transfected with 15µg 











 of cells were then replated onto 100mm dishes and allowed to grow for 
15days. Digital images from scanned plates are shown. Successful NHE1 
overexpression was determined by Western blot. Detection of β-actin served as 



















3.14 PPARγ-Induced Repression of NHE1 Expression: A New 
Therapeutic Approach To Increase Breast Cancer Cells’ 
Sensitivity To Paclitaxel  
Next, we asked if PPARγ ligands, by repression of NHE1, could render cells 
more sensitive to taxol/ paclitaxel treatment. Taxol, or paclitaxel, is a drug used 
for treating certain women who have advanced breast or ovarian cancer. 
Paclitaxel is a compound extracted from the bark of the Pacific yew tree (Taxus 
brevifolia). Paclitaxel was first discovered in the 1960s during a large-scale plant-
screening program sponsored by National Cancer Institute (NCI). Interest in 
developing the drug increased in 1979 after scientists found that paclitaxel has a 
unique mechanism for preventing growth of cancer cells. In April 1994, FDA 
approved the use of paclitaxel for breast cancer that has recurred within 6 months 
after the completion of initial chemotherapy and for metastatic breast cancer that 
is not responding to combination therapy. However, like most cancer drugs, 
paclitaxel does have certain side effects, some of which can be serious.  
Hence, by using PPARγ ligands, we would like to test the possibility of 
increasing breast cancer cell’s sensitivity to paclitaxel. This means reducing the 
dose of paclitaxel used and thus reducing its side effects, yet not compromising 
on its anti-tumor efficacy. To test this, MCF-7, MDA-MB231, and T47D breast 
cancer cells were seeded and deprived as described in Materials and Methods. 
The cells were then treated with 3µM and 5µM 15d-PGJ2 for 16h prior to 
treatment with 10nM paclitaxel for 24h. Cell survival was then assessed by using 
MTT assays. Interestingly, it was observed that pretreatment of cells with 15d-
112 
 
PGJ2 indeed sensitize cells to paclitaxel treatment in MCF-7 and MDA-MB231 
cell lines. There was reduced MTT formation in cells that were pretreated with 
15d-PGJ2 prior to paclitaxel treatment, as compared to cells that were treated with 
paclitaxel alone (Figure 19A, B). However, similar observation was not seen in 
T47D cell lines (Figure 19C). It is interesting to note is that 15d-PGJ2 did not 
repress NHE1 expression as significantly in T47D cell line as compared to other 
breast cancer cell lines. This implies that NHE1 could be the confounder that 
leads to increased sensitivity of breast cancer cells to paclitaxel treatment because 
cells (T47D) in which NHE1 expression was not repressed significantly did not 
seem to respond better to paclitaxel treatment. 
Hence, it is logical to ask if NHE1 expression level is responsible for sensitization 
of breast cancer cells to paclitaxel treatment. For this, NHE1 expression was 
silenced in MDA-MB231 cell lines, the cells were then treated with 10µM 
paclitaxel for 24h. Sensitization of cells was then measured by using MTT and 
colony forming assays. Surprisingly, we observed that silencing NHE1 alone in 
these cells could senstitize the cells to paclitaxel treatment (Figure 19D). Colony 
forming assays further confirmed the results (Figure 19E). It was observed that 
there was much reduced colony formation upon paclitaxel in cells where NHE1 
expression is silenced. This is as compared to cells that were treated with control 
si (Figure 19D, E). From these experimental results, we deduced that NHE1 































Figure 19: Reduced NHE1 expression contributes to increase sensitivity of 
tumor cells to paclitaxel treatment.
(A) MCF7, (B) MDA-MB231 and (C)
cells/12-well dish in duplicate. Cells were then treated with 3µM and 5µM 15d
PGJ2 for 16h prior to treatment with 10nM paclitaxel for 24h. Cells were assayed 





 T47D cell lines were seeded at 






triplicate. (D) Expression of NHE1 was silenced in MDA-MB231 cells using 
NHE1 specific siRNA. Forty eight hours following silencing, cells were treated 
with 10nM paclitaxel for 24h. Cells were then assayed by MTT. Data represents 
the average +/- SD of two experiments done in triplicate. (E) For the same set of 
experiment as (D), 1.5X10
4
 of cells were then replated onto 100mm dishes and 
allowed to grow for 10 to 15 days in RPMI supplemented with 10% FBS. Digital 














3.15 Treatment Of MCF-7 Breast Cancer Cells With 15d-PGJ2 
Causes Changes In Plasma Membrane Integrity 
Activation of PPARγ has been found to induce cell death in a variety of cells. It 
was reported that 15d-PGJ2 is able to inhibit proliferation and induces cellular 
differentiation and apoptosis in MCF-7 breast cancer cell line (Miguel Pignatelli 
et al., 2005). The group demonstrated that 15d-PGJ2 initiates breast cancer cell 
death via a very rapid and severe impairment of mitochondrial function, 
generation of ROS and a decrease in oxygen consumption. However, the drug 
concentration that this group used is double (10µM) the dose that we used. This 
probably explains the discrepancy and differences in observation of cell arrest 
mechanism (shown later). 
In the present study, we investigated the mechanisms underlying 15d-PGJ2-
mediated cell growth arrest in MCF-7 human breast cancer cells. Microscopic 
observation showed that MCF-7 cells begin to round up and detach from the 
bottom of wells as early as 8h after treatment with 3µM and 5µM 15d-PGJ2 
(Figure 20A). Detachment of cells from the well was further confirmed via 
crystal violet assays where reduction in cell density was observed upon treatment 
of MCF-7 cells with increasing doses of 15d-PGJ2 for 24h and 48h (Figure 20B). 
Rapid changes in cell morphology and cell density suggest that changes could 
also be occurring at the level of plasma membrane. Hence, we are interested to 
further investigate the biological profile of these cells upon treatment with 
PPARγ ligands.  
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Propidium iodide (PI) staining method was employed to assess whether the 
plasma membranes of cells treated with 15d-PGJ2 were undergoing permeability 
changes. Propidium iodide staining was performed on MCF-7 cells treated with 
3µM and 5µM 15d-PGJ2 for 4, 8, 16 and 26 hours. Surprisingly, as early as 8 
hours upon treatment with PPARγ ligands, drastic increase in percentage of cells 
that were stained with propidium iodide dye was observed (Figure 20C).  
Propidium iodide (PI) binds to nucleic acid. Once the dye is bound to nucleic 
acis, its fluorescence is enhanced 20- to 30- fold. Propidium iodide dye is also 
membrane impermeant and is generally excluded from viable cells. Increase in 
percentage of cells stained with PI implies decrease in percentage of viable cells. 
In other words, membranes of MCF-7 cells were permeabelized soon after 
PPARγ ligands treatment. Besides, the effect of 15d-PGJ2 also occurred in a dose-
dependent manner. These data suggest that a relatively early effect of 15d-PGJ2 is 
to cause disturbances in the plasma membrane, resulting in a loss of integrity and 
eventually cell arrest in MCF-7 breast cancer cells. Similar observations were 
reported elsewhere with prostate cancer cells (Butler et al., 2000).  
Next, we asked if this could be an early event of apoptosis. Hence, we 
preincubated MCF-7 cells with 50µM pan-caspase inhibitor ZVAD-fmk for 2h 
prior to treatment with 15d-PGJ2. ZVAD-fmk works by binding irreversibly to 
the catalytic site of all caspases through an aspartic acid residue mimicking the 
cleavage site, by fluoromethyl ketone (fmk) group forming a covalent inhibitor-
enzyme complex. Interestingly, ZVAD was able to block PI uptake in cells 
treated with 15d-PGJ2 (Figure 20D). This suggests that PPARγ agonists induced 
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Figure 20: 15d-PGJ2 induces changes in plasma membrane integrity is 
blocked by ZVAD-fmk 
(A) 1.5X10
5
 cells/12-well dishes were seeded in duplicate. Cells were then 
treated with 5µM 15d-PGJ
at 4h, 8h, 16h and 26h after treatment. (B)
seeded in duplicate. Cells were then treated with 1µM, 3µM and 5µM 15d
for 24h and 48h. At the end of treatment, cells remaining in culture dish were 
quantified using crystal violet assay as described in Materials and Method





2 for various durations. Pictures of cells were captured 
 1.5X10
5
 cells/12-well dishes were 






Following the same experimental conditions described in (B), percentage of cells 
that take up PI dye was measured by using laser scanning cytometry at 2h, 4h, 8h, 
16h and 26h after drug treatment. Data represents the average +/- SD of two 
experiments done in triplicate. (D) Following the same experimental conditions in 
(C), MCF-7 cells were pretreated with 50µM ZVAD-fmk prior to treatment with 















3.16 15D-PGJ2 Induced G1 Cell Cycle Arrest In MCF-7 Cells Is 
Blocked By ZVAD 
Peroxisome proliferator activated receptor gamma (PPARγ) ligands induced cell 
death was reported in a wide variety of experimental cancer models, both in vitro 
and in vivo (Konopleva M, 2002; Haydon RC, 2002; Panigraphy D, 2003; Debril 
M-B, 2001). 15d-PGJ2, in particular, was reported to induce programmed cell 
death in breast cancer cells (Pignatelli et al., 2005). This observation prompted us 
to assess if the growth inhibitory effect of PPARγ ligands would affect cell cycle 
progression in breast cancer cells. To investigate this, MCF-7 cells were treated 
with 15d-PGJ2 for flow cytometry analysis following cell fixation and DNA 
staining with propidium iodide. Consistent with our previous findings, dot-plot 
analysis showed that cells that were treated with 3µM and 5µM 15d-PGJ2 have 
reduced cell size. However, there is no increase in granulation in cells, as would 
be expected of cells undergoing apoptosis. There was also no increase in 
percentage of cells in sub-G1 phase upon treatment of cells with 15d-PGJ2 for 24h 
(Figure 21A). Similar observation was made in 48h and 72h (data not shown). 
Interestingly, there is a consistent trend towards arrest of cells in G1 phase, 
though not drastically (Figure 21A).  
Our previous experiments showed that pan-caspase inhibitor ZVAD was able to 
maintain plasma membrane integrity of cells by blocking 15d-PGJ2 induced 
plasma membrane leakage. The activation of caspases by 15d-PGJ2 has been 
shown in a variety of cancer cell types (Chattopadhyay et al., 2000; Keelan et al., 
1999; Rohn et al., 2001). Next, we are interested to know if by maintaining 
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plasma membrane integrity, is pan-caspase inhibitor ZVAD-fmk able to block 
15d-PGJ2 induced G1 arrest. Similar experiment was being set up. MCF7 cells 
were preincubated with 50µM ZVAD for 2h prior to treatment with 15d-PGJ2 for 
24h. Cells were then analyzed by flow cytometry following cell fixation and 
DNA staining with propidium iodide. Interestingly, apart from maintaining 
plasma membrane integrity of cells, it was observed that ZVAD could also rescue 
MCF7 cells from 15d-PGJ2 induced G1 cell arrest (Figure 21B). Similar 
observation was seen on cells that were stained with crystal violet. Figure 21C 
showed that ZVAD is able to block 15d-PGJ2 induced decrease in cell 





























Figure 21: PPARγ agonists induced G1 arrest in MCF-7 cells is blocked by 
ZVAD. 
MCF7 cells were seeded at 3X10
5
 cells/6-well dish as described in Materials and 
Methods. Cells were then treated with (A) 3µM and 5µM 15d-PGJ2, (B) 50µM 
ZVAD prior to treatment with 15d-PGJ2 for 24h. At the end of the incubation, 
cells were harvested for cell cycle analysis as described in Materials and 
Methods. (C) Following the same experimental conditions described in (A) and 
(B), cells remaining in culture dish was quantified using crystal violet assay as 
described in Materials and Methods. Data represents the average +/- SD of two 












3.17 Effects of 15d-PGJ2 on NHE1 expression is only minimally 
reactive oxygen species (ROS) dependent 
Viewing the early event of 15d-PGJ2 induced increase in cell membrane 
permeability (8h) and G1 arrest observed at 24h onwards, we asked what could 
possibly be the upstream induction that leads to these events. Although we 
showed that PPARγ induces decrease in NHE1 expression, and NHE1 was also 
previously shown to be a crucial regulator in cell survival; however, changes in 
cell membrane permeability occurred before change in NHE1 expression was 
observed. Hence, we wanted to determine other contributing factors that lead to 
the early changes induced by PPARγ ligands. Perez-Ortiz et al. showed that 
rosiglitazone at concentrations of 5-20µM decreased survival of glioma cells 
without affecting primary astrocytes by a mechanism mediated by an increase in 
mitochondrial-generated reactive oxygen  species (ROS) (Perez-Ortiz et al., 
2004). Several studies have also demonstrated that biochemical modifications 
represent an alternative apoptotic pathway (Kroemer, 1997). Reactive oxygen 
species are per se inducers of apoptosis and several drugs are able to induce the 
apoptotic program through generation of ROS (Kroemer, 1997). Besides, 
previous studies from our laboratory had also showed that H2O2 down regulates 
NHE1 transcription via oxidative activation of caspases 3 and 6 (Akram et al., 
2006; Kumar et al., 2007). Based on our published data, it is therefore pertinent 
for us to question if ROS is produced upon treatment of MCF-7 cells with 15d-
PGJ2 and if so does ROS plays a role in PPARγ induced decrease in NHE1 
protein expression.  
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To assess this, we first determine ROS generation in MCF-7 cells upon treatment 
with various doses of 15d-PGJ2. Surprisingly, we observed excessive ROS 
production as early as 15mins upon treatment of cells with 15d-PGJ2. Reactive 
oxygen species production is especially distinctive at 2h after treatment (Figure 
22A). Next, to further explore the effects of 15d-PGJ2 induced ROS production to 
the overall repression of NHE1 transcription,  MCF-7 cells were transiently 
transfected with full length (-1374/+16, contains PPRE region) human NHE1 
promoter and a 5’ deletion construct lacking PPRE region (-850/+16) of the 
human NHE1 promoter. The reason for using these two promoter constructs is 
because the PPRE is located at the 5’-end of the -1374/+16 construct but absent 
in the -850/+16 construct. However, both constructs do contain the previously 
identified H2O2 response region (Kumar et al., 2007). Cells were then treated with 
varying doses of 15d-PGJ2 for 24h. Promoter activity was then analyzed by CAT 
ELISA assay. As shown in Figure 22B , 15d-PGJ2 at 3µM induced a 60% drop in 
NHE1 promoter activity from the -1374/+16 construct. No drop in promoter 
activity is observed from the PPRE-deleted -850/+16 construct, suggesting NHE1 
down-regulation by 15d-PGJ2 at 3µM is solely PPARγ-dependent (Figure 22B). 
Interestingly, while 15d-PGJ2 at 5µM induced an 80% drop in NHE1 promoter 
activity (see -1374/+16 construct), the same concentration of 15d-PGJ2 induced a 
20% drop when using the -850/+16 promoter construct. Since the -850/+16 
construct lacks PPRE but retains H2O2 response region (Kumar et al., 2007), we 
infer that ROS contribution from using 5µM 15d-PGJ2 accounts for 
approximately 20% of the overall down-regulation of NHE1 transcription. The 
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remaining 60% drop in NHE1 gene transcription by 15d-PGJ2 at 5µM is from the 
transrepression activity of PPARγ (Figure 22B).  
We next questioned if we would also determine contribution of ROS from 15d-
PGJ2 exposure at the level of NHE1 protein expression. For this, MCF-7 cells 
were transfected with a plasmid encoding human catalase gene. As shown in 
Figure 22D, over expression of catalase prevented 10% drop of the total 60% 
drop in NHE1 protein levels when cells were exposed to 5µM 15d-PGJ2, this 
almost corroborated with the percentages observed at the transcription level. The 
differences in total drop seen at the level of NHE1 transcription (80%) (Figure 
25E) versus protein (60%) (Figure 22C) may be due to the long half life of NHE1 
protein (Cavet et al., 2001). Nevertheless, we show that 15d-PGJ2-induced NHE1 











































Figure 22: Effects of 15d
MCF-7 cells were exposed to 1µM and 5µM 15d
60mins, 120mins, 240mins and 360mins. (Ai) Graphical representation of DCF 
fluorescent for MCF7 cells from laser scanning cytometry (LSC) as described in 
Materials and Methods. Data is represented as percent increase DCF fluorescence 
in each cell line from untreated cells. Data represents the average +/
experiments done in duplicate. (Aii)
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transiently transfected with full length (-1374/+16, contains PPRE region) human 
NHE1 promoter and a 5’ deletion construct lacking PPRE region (-850/+16) of 
the human NHE1 promoter. Cells were treated with varying doses of 15d-PGJ2 
for 24h. Promoter activity as analyzed by CAT ELISA assay (Roche). NHE1 
activity expressed as percent decrease from untreated. (C) MCF-7 cells 
transfected with catalase over expressing plasmid or empty vector. Cells were 
then treated with varying doses of 15d-PGJ2 for 24 hours. NHE1 expression as 
analyzed by Western blot. Total protein extract from the indicated cell lines was 
analyzed using monoclonal antibodies against human catalase and human NHE1. 
















3.18 15d-PGJ2 Induces ROS Production Via PPARγ Dependent 
Mechanism 
Oxidative stress is increasingly seen as a major upstream component in the 
signaling cascade involved in many of the cellular functions, such as cell 
proliferation, inflammatory responses, stimulating adhesion molecule, and 
chemoattractant production. It has been suggested that some level of oxidative 
stress may be required in response to cytotoxic agents and converted into the 
redox regulatory system as a downstream signaling pathway. However, excess 
oxidative stress may be toxic, exerting cytostatic effects, causing membrane 
damage, and activating pathways of cell death (apoptosis and/or necrosis). 
Reactive oxygen species (ROS) generated during oxidative stress may be 
responsible for these effects due to their ability to damaged cellular components, 
such as membrane lipids. Besides, it was demonstrated that cyclopenteneone 
prostaglandins (PGs) of the J2 series, naturally occurring derivatives of PGD2, are 
potential inducers of intracellular oxidative stress that mediates cell degeneration 
(Kondo et al., 2001). Next, we wanted to know if there is any difference in ROS 
production in breast cancer cell lines that were treated with PPARγ agonists. 
Hence, we determine reactive oxygen species (ROS) generation in MCF-7, 
MDA-MB231 and T47D breast cancer cell lines by flow cytometry and laser 
scanning cytometry, looking for conversion of the non-fluorescent DCFH-DA 
into a fluorescent molecule through oxidation. Interestingly, it was observed that 
ROS production is more prevalent in MDA-MB231 and MCF-7 cells compared 
to T47D breast cancer cells. It is imperative to note that increase in ROS 
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production in these cells upon 15d-PGJ2 treatment correlates positively with basal 
PPARγ expression in these cells (Figure 23A, B). In other words, induction of 
ROS was more prevalent in cell lines that express higher PPARγ level. This 
suggests that ligation of PPARγ probably has a role to play in ROS production 
induced by PPARγ agonists. 
These observations led us to question if ROS production is a downstream event of 
PPARγ activation or a PPARγ-independent effect. Hence, we over expressed 
pcmX-mPPARγ in MCF7 cells to investigate if increase PPARγ expression in 
MCF7 cells would lead to increase ROS production upon trigger with 15d-PGJ2. 
In the absence of any drug treatment, ROS level in pcmX-mPPARγ transfected 
cells was consistently higher compared to cells that were transfected with pcmX 
empty vector (Figure 23C). This is probably because endogenous prostaglandins 
that are present in the cultured cells were able to activate PPARγ that was being 
over expressed. This serves at first line of evidence to show that ROS production 
was probably dependent on PPARγ expression. At 1 and 2 hours after treatment 
with 15d-PGJ2, ROS production in cells that over expressed PPARγ was again 
higher compared to cells that were transfected with control vector (Figure 23C). 
These observations further support our speculation that 15d-PGJ2 induces ROS 
production via PPARγ dependent mechanism. 
In order to further investigate the source of ROS production and the involvement 
of PPARγ, we preincubated MCF-7 cells with GW9662 for 2h prior to treatment 
with 15d-PGJ2. GW9662 is a PPARγ antagonist which forms cysteine 
modification at ligand binding site to prevent PPARγ from being activated. ROS 
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production was then measured in these cells by DCFH-DA staining. Interestingly, 
our data showed that GW9662 was able to block ROS production induced by 
15d-PGJ2 in MCF-7 cells (Figure 23D). This again suggests that activated PPARγ 
is responsible for ROS production induced by 15d-PGJ2; blocking PPARγ 
ligation would then reduce ROS production induced by 15d-PGJ2. However, one 
interesting observation to note is that GW9662 by itself was also able to produce 
ROS (Figure 26E). MCF-7 cells were seeded as described in materials and 
methods, the cells were then deprived, follow by treatment with various doses of 
GW9662 for 2h. ROS production was then measured via DCFH-DA staining. The 
results showed that although GW9662 could act as PPARγ antagonist and inhibit 
PPARγ induced ROS production, it is by itself a ROS producing agent. This 
could probably explain the discrepancy in our previous observation, which 
showed that GW9662 was able to block PPARγ activity (Figure 16) but unable to 
block PPARγ induced down regulation of NHE1 (data not shown). By acting as 
ROS producing agent itself, the inhibitory effects that GW9662 has on PPARγ 





















Figure 23 Effect of 15d-
three breast cancer cell lines
(A) MCF-7, MDA-MB-231, and T47D cells were exposed to 3µM and 5µM 
15dPGJ2 for 30 min and the DCF fluorescence intensity was measured by laser 
scanning cytometry (LSC). 
graphical representation showing ROS levels in the three cell lines with 5µM 
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Figure 23: Effects of PPARγ 
(C) MCF-7 cells were transfected with either pcmX (empty vector) or pcmX
mPPARγ. The cells were then treated with 3µM 15d
DCF fluorescence was then monitored 
cells were exposed to increasing doses of 15d
absence of 15µM GW9662, and the DCF fluorescence intensity was monitored by 
LSC. (E) MCF-7 cells were treated with increase doses of GW9662 for 2h. DCF 
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3.19 GW9662 Abrogates 15d-PGJ2 Induced Down regulation Of 
NHE1 Expression In Regular FBS Condition, But Not In 
Charcoal/Dextran Treated FBS Condition 
So far, our results suggest that probably both PPARγ and ROS are responsible for 
regulating NHE1 protein expression in breast cancer cell lines. Hence, agents that 
are able to inhibit PPARγ activation, but by itself produces ROS, might not be 
able to inhibit NHE1 expression fully. This is true in our experimental setting 
with GW9662. We were unable to inhibit NHE1 down regulation induced by 
PPARγ using GW9662, though GW9662 was shown to be able to inhibit PPARγ 
activity in our system. This is probably because charcoal/dextran FBS by itself 
induces high level of ROS production. Although GW9662 is able to block both 
PPARγ activation and also ROS production, it is by itself producing ROS. Hence, 
ROS that is produced by GW9662 might affect NHE1 expression, this will then 
interfere with its function as PPARγ antagonist.  
In order to overcome the interference due to ROS production from GW9662, we 
set up a separate experiment. MCF-7 cells were seeded in RPMI supplemented 
with 10%  regular FBS, instead of charcoal treated FBS. DCF analysis showed 
that ROS production in regular FBS condition is lower compared to 
charcoal/dextran FBS condition. The cells were then deprived overnight prior to 
treatment with GW9662 and 15d-PGJ2 for 24 hours.  Surprisingly, real time PCR 
analysis showed that GW9662 is indeed able to block PPARγ induced down 
regulation of NHE1 expression, in both MCF-7 (Figure 24A) and MDA-MB231 
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cells (Figure 24B), in this experimental setting, where ROS production is lower 


































Figure 24: GW9662 blocks 15d-PGJ2 induced NHE1 down regulation. 
(A) MCF-7 cells were seeded in RPMI supplemented with 10%  regular FBS. The 
cells were then deprived overnight prior to treatment with GW9662 and 15d-PGJ2 
for 24h. The lysates were then collected for real time PCR analysis. (B) The same 




3.20 15d-PGJ2 Induced Decrease in Cell Survival Is Partly 
Dependent On PPARγ Expression 
Next, we wanted to investigate if 15d-PGJ2 induced decrease in cell survival is 
dependent on PPARγ expression and activation or otherwise. Hence, we over 
expressed pcmX-mPPARγ in MCF-7 cells prior to treatment of cells with 15d-
PGJ2 for 24h.  Control set of cells were transfected using empty vector plasmid 
prior to the same drug treatment. To our surprise, there is enhanced suppression 
of cell survival upon treatment with 3µM of 15d-PGJ2 in cells that were 
transfected with pcmX-mPPARγ plasmid, which was not observed in cells that 
were transfected with empty vector (Figure 25A). However, this enhanced 
reduction in cell survival was not observed in cells that were treated with 5µM of 
15d-PGJ2. This suggests that 15d-PGJ2 induced decrease in cell survival via 
PPARγ dependent mechanism, at least partly, at lower drug concentration, but not 
at higher 15d-PGJ2 concentration (5µM).  
To further support the evidence that PPARγ is indeed imperative in 15d-PGJ2 
induced in cell survival, MCF-7 cells were treated with GW9662 for 2h prior to 
treatment with 15d-PGJ2. GW9662 acts as PPARγ antagonist by inducing 
cysteine modification at PPARγ binding region. However, to our disappointment, 
GW9662, though is able to block PPARγ activation, is unable to block 15d-PGJ2 
induced decrease in cell survival (Figure 25B). An explanation to this observation 
is that probably GW9662 is by itself a ROS producing agent, as shown previously 
in Figure 23E; and ROS was known to be able to reduce cell survival by its own. 
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This then leads to the speculation that apart from PPARγ, there could be other 







































Figure 25: PPARγ Expression Affects 15d
Survival 
MCF-7 cells were seeded as described in Materials and Methods. (A) Cells were 
transfected with either pcmX (empty vector) or pcmX
then treated with 3µM 
pretreated with GW9662 for 2h prior to treatment with 15d




-PGJ2 Induced Decrease In Cell 
-mPPARγ. The cells were 
and 5µM 15d-PGJ2 for 24h. (B) MCF7 cells were 
-PGJ2 for 24h. 




in Materials and Methods. Data represents the average +/- SD of two experiments 































3.21 Identifying ROS Species That Contribute To 15d-PGJ2 
Induced Decrease In Cell Survival 
In previous experiments, we showed that PPARγ is able to induce abundant ROS 
production in breast cancer cells. Although ROS has important roles in cell 
signaling, high ROS levels can also result in significant damage to cell structures.  
Hence, we wanted to know if ROS does play a role in 15d-PGJ2 induced decrease 
in cell survival in MCF-7 cells.  
As a next step in identifying the involvement of ROS in cell survival, NAC is 
being used. N-Acetyl Cysteine (NAC) is an amino acid and a thiolic antioxidant. 
This is because cysteine can be used in the production of the GSH. Glutathione 
(GSH) on the other hand, is a tripeptide that exists in the reduced form (GSH), 
and maintains a balance with its oxidized form (GSSG), a disulfide. It is the 
master antioxidant in our body. One way NAC can contribute to increase GSH 
levels is through deacetylation to create cysteine (Anderson and Luo, 1998). 
Apart from being a glutathione precursor, NAC is also a powerful antioxidant in 
its own right. It is an excellent scavenger of ROS/RNS, including HOCl, 
ONOOH, RO2, OH and H2O2). It also reduces hydrogen peroxide (Aruoma et al., 
1989) and superoxide (Benrahmoune et al., 2000), although much more slowly.  
To firstly identify the roles of ROS in 15d-PGJ2 induced decrease in cell survival, 
MCF-7 cells were preincubated with NAC for 2h prior to treatment with 15d-
PGJ2 for 24h. Cells were then analyzed via both crystal violet and colony forming 
assays. Interestingly, preincubation of MCF-7 cells with 5mM NAC prior to 
treatment with 5µM of 15d-PGJ2 revived the dying cells. However, this 
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observation was not seen at 3µM of 15d-PGJ2 treatment. This experiment was 
conducted via crystal violet assays (Figure 26A). Colony forming assays, on the 
other hand, showed that 5mM NAC can rescue MCF-7 cells both at 3µM and 
5µM of 15d-PGJ2 treatment (Figure 26B). These results strongly suggest the 
involvement of ROS in 15d-PGJ2 induced decrease in cell survival at 5µM, and 
probably at 3µM.  
Next, we asked if NAC could also similarly rescue cells from G1 arrest induced 
by PPARγ ligands. Similar experiments were set up and cell cycle profile was 
analyzed via flow cytometry. It was shown that NAC can indeed block G1 arrest 
induced by PPARγ ligands. In the presence of NAC, percent cells that were 
arrested at G1 falls below control (nontreated cells) (Figure 26C). This shows that 
NAC, by acting as antioxidant, prevent cells from the effects of PPARγ ligands, 
at both 3µM and 5µM of 15d-PGJ2 treatment. This again suggests that ROS plays 
significant roles in influencing viability of cells at both low and high 
concentrations of 15d-PGJ2, unlike PPARγ expression which was shown to be 
able to influence 15d-PGJ2 induced decrease in cell survival only at lower drug 
concentration (3µM).  
Reactive oxygen species in the system was measured via DCFHDA staining. 
Increase in fluorescent was due to oxidation of the dye by hydrogen peroxide, 
hydroxyl radical or peroxynitrite. To investigate the species of ROS, various ROS 
scavengers, such as DMTU and catalase were used for investigation. 
Dimethylthiourea (DMTU) is a hydroxyl radical scavengers whereas catalase 
scavenges hydrogen peroxide. It was observed that both DMTU (Figure 27A) and 
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catalase were unable to protect MCF-7 cells from 15d-PGJ2 induced decrease in 
cell survival. This implies that probably hydroxyl radicals and hydrogen peroxide 
are not critical in affecting cell survival in this system. 
The next possible ROS that could possibly play a role is then peroxynitrite. 
Hence, MCF7 cells were pretreated with 10µM 5,10,15,20-Tetrakis(4-
sulfonatophenyl) prophyrinato iron (III), chloride (FeTPPS) prior to treatment 
with 15d-PGJ2 for 24h. FeTPPS is a peroxynitrite scavengers. It is a ferric 
porphyrin complex that catalytically isomerizes peroxynitrite to nitrate both in 
vivo and in vitro, hence providing cytoprotection against peroxynitrite (Misko et 
al., 1998). Cell survival was then measured via crystal violet assays. It was 
observed that FeTPPS could protect cells from 15d-PGJ2 induced cell death, at 
both 3µM and 5µM treatment (Figure 27B). As a next step to confirm the role of 
peroxynitrite in 15d-PGJ2 induced decrease in cell survival, two other scavengers 
were being used, LNMMA and tiron. LNMMA is an inhibitor for nitric oxide 
synthase while tiron is a superoxide scavengers. Peroxynitrite is produced from 
both nitric oxide and superoxide. Hence, we wanted to see if by inhibiting the 
production of these two radicals, were we able to rescue cells from 15d-PGJ2 
induced effects. In fact, we observed a rescue with LNMMA pretreated cells 
(Figure 27C). However, this rescue was not noticed in tiron pretreated cells (data 
not shown). This is probably because the concentration of tiron that was used is 
not optimized yet. Hence, more works need to be done in order to confirm the 
involvement of peroxynitrite in 15d-PGJ2 induced decrease in cell survival in 
breast cancer cells.  
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 A pitfall of the use of ROS scavengers is the potential non-specific effects of the 
chemicals. Importantly, NAC, FeTPPS and LNMMA rescued cells from 15d-
PGJ2 induced cell death, while DMTU, catalase and Tiron did not show these 
effects. The results suggest that the fraction of ROS that is inhibited by NAC, but 
not by DMTU, could be a different species of free radicals. This radical is then 
very likely to be peroxynitrite, based on the experimental evidence that we have 



























































































Figure 26: N-Acetyl Cysteine (NAC)
Decrease In Cell Survival
MCF-7 cells were seeded as described in Materials and Methods. Cells were 
pretreated with 5µM NAC for 2h prior to treatment with 15d
Viability of remaining cells in culture dish was a
C 
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 Is Involved In 15d-PGJ2 Induced 
 
-PGJ2 for 24h. 




assays, (B) colony forming assays, (C) propidium iodide staining. Data represents 


































































Figure 27: Reactive Oxygen Species (ROS) That Is Involved In 15d
Induced Decrease In Cell Survival
MCF-7 cells were seeded as described in Materials and Methods. Ce
pretreated with 50mM DMTU






 for 2h prior to treatment with 15d-PGJ2
2 
lls were 
 for (Ai) 
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for ROS production via DCFHDA staining. MCF-7 cells were also pretreated 
with (B) 10, 20µM FeTPPs and (C) 250, 500µM LNMMA. Viability of 
remaining cells in culture dish was analyzed via crystal violet assays. Data 



















4. DISCUSSIONS/ CONCLUSIONS 
 
The peroxisome proliferator-activated receptors (PPARs) are ligand-activated 
transcription factors that belong to the nuclear hormone receptor superfamily. 
Three subtypes, PPARα, PPARβ/δ and PPARγ, have been identified and these 
subtypes have high sequence conservation across various species. The DNA 
binding domains of the three subtypes are 80% identical, while their ligand-
binding domains exhibit a lower degree (approx. 65%) of identity. Consistent 
with the relatively high divergence among the subtype-specific ligand binding 
domains, differential activation of PPARs by endogenous and exogenous 
compounds may account for the specific biological activity of the three PPAR 
subtypes (Desvergne and Wahli, 1999). 
In the past twenty years, more than 70 PPAR target genes with functional PPREs 
have been identified and confirmed experimentally. However, this list of genes is 
skewed towards the targets involved in fatty acid metabolism and adipocyte 
differentiation, as these two functional pathways serve as the prime focus in these 
studies. Peroxisome Proliferator-activated receptor (PPARs) target genes are such 
as lipoprotein lipase (LPL), fatty acid transporter protein (FATP), adipocyte fatty 
acid-binding protein aP2, acyl-CoA synthetase (ACS), phosphoenolpyruvate 
carboxy kinase (PEPCK), and malic enzyme (ME). These are known as adipose 
differentiation-related protein (adrp). Adipose differentiation-related protein 
(ADRP) is a 50kDa protein expressed at high level in differentiated adipocytes. 
ADRP expression is very low in undifferentiated adipocytes and increases rapidly 
and dramatically as the cells undergo adipose differentiation. Subsequent analyses 
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revealed that all PPARs induced human adrp gene expression through the same 
PPRE of the ADRP promoter, while unliganded PPARδ repressed this gene 
(Tachibana et al., 2005).  
In 2005, a genome-wide search has been conducted for the high-score PPREs in 
conserved elements of the 5000 base pairs upstream of all human reference genes 
(Yu et al., 2005). Housekeeping genes are commonly used as endogenous 
reference genes for the relative quantification of target genes in gene expression 
studies. The general conditions a reference gene must meet is that its expression 
in the samples studied be stable, non-regulated and constant and not be influenced 
by biological (e.g., age, gender, metabolism, disease stage) or experimental (e.g., 
addition or deprivation of physiological, physical or chemical agents) conditions 
or treatments. In addition, the reference gene and the target gene should have 
similar ranges of expression to avoid analytical problems. Surprisingly, when 
gene ontology (GO) annotations were retrieved, genes involved in cell cycle 
arrest, apoptosis and DNA damage response were shown to be a more likely 
target for PPARs than those involved in fatty acids metabolism. These are genes 
that are involved in functional categories embracing the regulation of 
transcription and chromatin remodeling and included genes HDAC1 and HDAC3. 
This discovery contradicted the usual believe that PPARs target genes are only 
involved in fatty acid metabolism and adipocyte differentiation. However, the 
functional relevance of computational prediction of PPRE data collected awaits 
experimental investigation for confirmation.  
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Among the various subtypes of PPARs, PPARγ has been extensively studied. The 
PPARγ quickly evolved over the last decade from a new orphan receptor to one 
of the best characterized nuclear receptors. A fast pace in PPARγ research was 
triggered by two main discoveries. Firstly, that PPARγ, similar to all other 
PPARs, was shown to have a key role in adipogenesis as mentioned previously. 
Initial studies reported a high level of PPARγ expression in adipocytes and its 
regulatory roles in adipogenesis, lipid metabolism and glucose homeostasis 
(Lehmann et al., 1995; Tontonoz et al., 1994). Secondly, the discovery that its 
synthetic ligands, the thiazolidinediones, are promising insulin sensitizing drugs, 
which are currently being developed and used  for the treatment of Type II (non-
insulin-dependent) diabetes mellitus. More recently this nuclear receptor also 
emerged from a role limited to metabolism (diabetes and obesity) to a “power 
player” in gene transcriptional control of numerous cellular processes, with 
implications in cell cycle control, carcinogenesis, inflammation, atherosclerosis 
and immunomodulation (Greene et al., 1995; Rosen and Spiegelman, 2001).  
Initially, it was discovered that PPARγ activation induced differentiation of 
preadipocytes to adipocytes was associated with cell cycle arrest (Altiok et al., 
1997). Then it was found that PPARγ ligands were also able to induce cell cycle 
arrest and terminal differentiation in liposarcoma cells (Tontonoz et al., 1997). 
These findings suggested a plausible link between PPARγ-activation and 
induction of cellular differentiation and cell cycle arrest. Recently, various reports 
have repeatedly shown that breast cancer cells express higher level of PPARγ as 
compared to normal breast epithelial cells (Brockman et al., 1998; Elstner et al., 
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1998; Tontonoz et al., 1997). This has led to further studies to investigate whether 
PPARγ ligands could induce differentiation or cell cycle arrest and thus growth 
inhibition of tumor cells of different tissue origins (Brockman et al., 1998; Elstner 
et al., 1998; Kubota et al., 1998; Mueller et al., 1998a; Sarraf et al., 1998). These 
widened roles of PPARγ will certainly initiate a new flurry of research, which 
will not only refine our current often partial knowledge of PPARγ but more 
importantly also establish that this receptor has a definite role as a primary link 
adapting cellular, tissue and whole body homeostasis to energy stores (Auwerx, 
1999).  
However, the relationship between PPARγ expression and tumors development 
has not been clearly identified. A link between PPARγ and breast cancer was first 
drawn after it became clear that overexpression of PPARγ in human breast cancer 
cell lines could be activated to inhibit proliferation, cause extensive lipid 
accumulation, reduce growth rates and cologenic capacity and promote the 
emergence of phenotypic changes associated with a more differentiated and less 
malignant status of cancer (Mueller et al., 1998a). Very often, cancers are 
associated with dsyregulation of the balance between proliferation and apoptosis. 
To inhibit proliferation and/or induce apoptosis through ligands of nuclear 
hormone receptors (NHRs) is thus a recent approach to cancer therapy. The proof 
of the principal for this approach was demonstrated by the treatment of acute 
promyelocytic leukemia (APL) using the retinoic acid (RA) receptor (RAR) 
specific ligand, all-trans-RA (ATRA) (Warrell et al., 1991) as well as the use of 
retinoids for early lesions of head and neck cancer (Hong et al., 1990) and 
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squamous cell carcinoma of the cervix (Lippman et al., 1992). A phase II clinical 
trial using PPARγ ligands has been recently performed as a novel therapy for 
advanced breast cancer patients (Burstein et al., 2003). Besides, a recent study 
also showed that PPARγ ligands inhibit the proliferation of breast cancer cells by 
repressing cyclin D1 expression (Wang et al., 2001). The cyclin D1 proto-
oncogene is an important regulator of G1 to S-phase transition. It is also a protein 
that causes drug resistance in many breast cancer patients. Thus, it is very 
important to obtain a better understanding of the clinical and/or biological roles of 
PPARγ in breast cancer tissues in order to improve the potential clinical 
efficiency of PPARγ ligand therapy for breast cancer patients. 
It was also demonstrated that breast cancer cells have significant lipogenic 
capacity; hence inhibition of fat metabolism in these cells is associated with their 
growth arrest and apoptosis (Pizer et al., 1996; Willett et al., 1992). Several 
agents that promote differentiation of adipocytes are PPARγ ligands including 
several prostanoids, of which 15-deoxy-delta(12,14)-prostaglandin J(2) (15d-
PGJ2) is the most potent, as well as members of a new class of oral antidiabetic 
agents, the thiazolidinediones and a variety of non-steroidal anti-inflammatory 
drugs (NSAIDS). During the last seven years, studies have reported antitumor 
effects of various PPARγ ligands on almost every kind of tumor cells. However, a 
parallel line of findings came up regarding the tumor promoting effects of PPAR-
activation (Lefebvre et al., 1998; Lucarelli et al., 2002; Saez et al., 2004; Saez et 
al., 1998). There are several recent studies that do not support PPARγ prospective 
therapeutic use against cancer (Bell-Parikh et al., 2003; Ishihara et al., 2004). It 
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has been demonstrated that PPARγ expression is significantly lower in breast 
cancer tissues at both mRNA and protein levels than that in normal tissues 
(Watkins et al., 2004). Expression of PPARγ has been examined in human breast 
carcinoma by several groups, but little information is available on the 
clinicopathological features of PPARγ-positive breast cancers. These 
observations thus contradict the role of PPARγ as anti-tumor agent. Therefore, 
the biological significance of PPARγ remains largely undetermined in human 
breast carcinoma.  
Recently, it was demonstrated that troglitazone, a thiazolinediones group of 
antidiabetic drugs, induces cellular acidosis via inhibition of the active extrusion 
of acid via NHE. Troglitazone-induced cellular acidosis in the cell lines tested 
was also demonstrated in another compound of the same family of 
thiazolidinedione, which are PPARγ agonists (Turturro et al., 2004). Research 
done in our laboratory has also demonstrated that downregulation of NHE1 gene 
increases sensitivity of cells to death triggers (Akram et al., 2006). The 
physiological roles of NHE1 have been thoroughly studied, and have proven to be 
diverse. The most basic role of NHE1 is in pHi and cell volume control (Putney et 
al., 2002). Our continued findings also seem to suggest the importance of PPARγ 
in influencing the survival of cells, especially tumor cells!  
In this study, we first examined immunolocalization of PPARγ in normal and 
tumor breast tissues. Our initial observation showed that tumor breast tissues have 
much higher immunoreactivity for PPARγ and NHE1 as compared to normal 
breast tissues (Figure 5A, B). This finding is consistent with the results that were 
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reported previously (Elstner et al., 1998). A more in-depth investigation thus 
leads us to the observation that PPARγ that was present was shown to be 
localized at the cytoplasm while NHE1 is found at the membrane of cells. This 
suggests that high level of PPARγ that is present in tumor breast tissues are 
probably not activated because nuclear receptor needs to be translocated into the 
nucleus to perform its transcriptional regulator functions. Microscopic analysis on 
various sections of the breast tissues repeatedly showed that PPARγ expression is 
primarily cytoplasmic. On the other hand, immunohistochemical and microscopic 
analysis showed that NHE1, being a plasma membrane protein, has a membrane 
locale. Coincidently, higher immunoreactivity of NHE1 protein was observed in 
tumor breast tissues (Figure 5A, B) as compared to normal breast tissues. Hence, 
correlative evidence from breast tissue samples showed that higher PPARγ 
expression in the cytoplasm is accompanied by higher NHE1 protein expression 
at the plasma membrane.  
Hence, our study was triggered by the observations that PPARγ agonists, both 
troglitazone and rosiglitazone, induced cellular acidosis in cells via inhibition of 
NHE1. Intracellular acidosis in turn determines sensitivity of cells to death 
triggers. Recent studies have shown that an alkaline pHi is a fundamental step in 
the acquisition of an induced tumorigenic phenotype in various cells (Gillies et 
al., 1990; Reshkin et al., 2000). Despite the fact that tumor cells grow in an acidic 
milieu, they present enhanced glycolysis that enables both endogenous acid 
production and their reliance on acid extrusion mechanisms (Kallinowski et al., 
1988; Patel et al., 2001a; Vaupel et al., 1989). Whereas extracellular acidosis 
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favors tumor growth, cellular acidosis leads to p53-dependent induction of 
apoptosis in various tumor-derived cell lines (Gatenby and Gawlinski, 2003; 
Williams et al., 1999). On the other hand, the permissive role of elevated pHi 
favors DNA synthesis and promotes tumor growth (Lee et al., 2003; Pouyssegur 
et al., 1985). Hence, the acid-base balance in tumors has been targeted for 
therapeutic purposes through interference with the function of NHE1 and related 
biochemical pathways.  
Through immunohistochemical analysis, we showed that PPARγ and NHE1 
expression are higher in tumor breast compared to normal breast epithelial 
tissues. This  observation led us to raise a question. Why would breast cancer 
cells harbor higher PPARγ expression if PPARγ agonists can induce cellular 
acidosis in cells which eventually sensitize cells to death trigger? We then 
realized that it has been demonstrated that at physiological concentrations, TZD 
and 15d-PGJ2 are shown to inhibit serum-deprivation induced apoptosis of the 
clonal kidney cell line LLC-PK1 (Haraguchi et al., 2002). In other words, 
physiological concentration of PPARγ agonists is beneficial for cancer cells. 
Indeed low doses of PPARγ agonist has been shown to increase cell proliferation 
(ref). 
Hence, pharmacological induced activation of PPARγ in tumor tissues, where 
PPARγ expression is abundant, would provide an excellent manipulative channel 
to combat tumor cells’ proliferation.. Normal cells, on the other hand, would 
probably be minimally affected due to its low PPARγ expression! 
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Thsi hypothesis led us  to investigate on both PPARγ and NHE1 and to identify if 
NHE1 can be a PPARγ target gene and if this regulation plays essential roles in 
sensitizing breast cancer cells to death trigger. Although reports demonstrated 
that PPARγ could act as nuclear transcription factor, specific genes 
transcriptionally regulated by PPARγ ligands in cancer cells which  induces anti-
proliferative activity still remains unclear. Previously, transcriptional 
upregulation of PTEN that inhibits PI3-kinase and PKB was shown to be linked 
to rosiglitazone induced growth inhibitory and anti-inflammatory effects (Patel et 
al., 2001b). However, later studies failed to detect any such changes in PTEN 
expression (Hong et al., 2003; Shao et al., 2002).  
As a first step for our investigation, we identified a functional PPRE in the human 
NHE1 promoter located between nucleotide (nt) –977 to –990 with respect to the 
TATA box (Accession number: L25272). This PPRE sequence is highly similar 
to PPRE that was previously shown to be present at promoter region of 
myeloperoxidase gene (ref). An attempt to identification a PPRE in the promoter 
region of NHE1 would be very useful because NHE1 was shown to be involved 
in normal processes such as cell proliferation, growth, migration, and apoptosis 
and pathological processes such as cancer cell invasion and heart failure 
(Harguindey et al., 2005; Karmazyn et al., 2005). However, the PPRE that was 
identified at promoter region of NHE1 contained DR2 repeats instead of the 
conventional DR1 (Figure 7B). It varies slightly from the conventional consensus 
sequence that is present in most PPRE of PPARγ target gene. Interestingly, 
studies have shown PPARγ could also bind to a DR2 element (Schoonjans et al., 
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1997; Kliewer et al., 1992; Huang et al., XXX; Fontaine et al., XX; Kumar et al., 
2004) 
 
Our results showed that there is a putative PPRE within Alu element in the 
promoter region of NHE1 gene. Hence, presence of PPRE in the promoter region 
of NHE1 might also allow PPARγ to bind and regulate its expression. In order to 
investigate the ability of PPARγ to interact with DR2 at promoter region of 
NHE1, chromatin immunoprecipitation and lighshift assays were performed. 
Chromatin immunoprecipitation (ChIP) method provides an advantagenous tool 
for investigating these protein-DNA complexes as compared to lightshift assay. 
Protein-DNA complexes formed on chromosomes are key platforms for the 
related signal transduction pathways in the nucleus. Whereas lightshift assay 
analyzes direct interactions between protein and DNA in vitro, the ChIP method 
is suitable for detecting the interactions between protein of interest and DNAs 
with known sequences in vivo. Interestingly, using both of these assays, we 
demonstrate that PPARγ is indeed able to bind to hormone response element 
(HRE) (DR2 as shown in Figure 7B) that is present in the Alu sequences within 
promoter region of NHE1. Lightshift assay   show that a nuclear protein from 
MCF7 and MDA-MB231 cells binds to PPRE. The ability of anti-PPARγ 
antibodies to subsequently diminish the mobility of the biotin-labelled probe 
indicates that PPARγ is indeed present in this protein-DNA complex. Although 
the binding pattern of other auxiliary proteins to the PPRE is not demonstrated, it 
is clear that PPARγ participates in PPRE binding. ChIP assay subsequently 
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confirms that PPARγ binds to HRE in vivo. Hence, the results of these two assays 
confirmed that PPARγ is able to bind to PPRE that is present at the promoter 
region of NHE1. 
Thus far, immunohistochemistry, sequence identification and subsequent protein-
DNA complex binding assays have shown promising results. These data suggest 
the possibility of NHE1 in being a PPARγ regulated gene. To further investigate 
the relevance of this binding in the context of breast cancer, few breast cancer and 
normal breast cell lines were utilized. MDA-MB231, MCF7 and T47D are among 
the breast cancer cell lines that express PPARγ with MDA-MB231 having the 
highest PPARγ expression of them all. MDA-MB231 is a poorly-differentiated 
cell while T47D is a well-differentiated breast cancer cell line. Besides, both 
MCF7 and T47D are estrogen positive cell lines whereas MDA-MB231 is not 
responsive to estrogen. These are all spontaneously occurring human breast 
adenocarcinomas. Despite the obvious differences in basal PPARγ expression that 
were shown by real time PCR (Figure 6B) and western blot analysis (Figure 6A), 
the basal PPARγ activities in these three cell lines were found to be rather similar, 
as depicted by luciferase reporter gene assay (Figure 8A). This refers to the level 
of activated PPARγ in cell lines when no exogenous ligands are added. This also 
suggests that the media contains components capable of activating PPARγ and 
thus maintaining it at some level of activation. It is also possible that the 
endogenous production of prostaglandins maintain PPAR in a constant state of 
activation in these cells. Corroborating with immunohistochemistry data that were 
obtained from tissue samples, this is probably because most PPARγ that is 
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present in the cells are in the cytoplasm. Immunohistochemistry analysis showed 
that most of the PPARγ is found in the cytoplasm, instead of nucleus, in both 
normal (Figure 5A) and breast tissue samples (Figure 5B). This is consistent with 
the observation that only minimal and similar amount of activated PPARγ that is 
present in cell lines to execute the physiological functions. Hence, although 
MDA-MB231 cells have much higher PPARγ expression as compared to the 
other two cell lines, its basal PPARγ activity is similar if not identical to MCF7 
and T47D cell lines. Interestingly, using western blot analysis, it was observed 
that PPARγ expression in these cell lines is inversely correlated to its NHE1 
expression (Figure 6A). This observation triggered us to postulate that PPARγ 
may be a repressor of NHE1 expression. 
At least three different levels of regulations  have been shown to be important in 
PPARγ activity modulation. First, ligand-binding modifies the conformation of 
PPARγ, regulating its transcriptional activity. Second, regulation of the PPARγ 
mRNA transcription increases or decreases PPARγ protein concentration. Finally, 
cofactor interactions result in the activation or repression of PPARγ target gene 
transcription (Miard and Fajas, 2005). In our investigation, we attempt to use all 
these three approaches to decipher the role of PPARγ in NHE1 regulation.  
We next wanted to explore if PPARγ agonists are able to regulate NHE1 
expression in these breast cancer cell lines. MCF7, MDA-MB231 and T47D cells 
were treated with various doses of PPARγ agonists, 15d-PGJ2. Members of the 
PGJ2 series have been reported to have their own unique spectrum of biological 
effects, including the inhibition of cell cycle progression, the suppression of viral 
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replication, the induction of heat shock protein expression, and the stimulation of 
osteogenesis (Fukushima, 1992). In contrast with the case of PGD2, the 
mechanism of action for the J2 series of PGs remains unclear. The observation 
that at least one of the PGJ2 series, 12-PGJ2, is actively incorporated into the 
nucleus of cells and associated with proteins (Narumiya et al., 1987) has led to 
speculation that these PGs may exert their effects through direct interactions with 
intracellular proteins. It was then been shown that the PGJ2 dehydration product 
15-deoxy-12,14-PGJ2 is able to bind directly to PPARγ (ref) 
 We showed that PPARγ ligands 15d-PGJ2, without altering PPARγ expression, 
could stimulate a PPRE -luciferase reporter construct in all the transfected cell 
lines, MDA-MB231, MCF7 and T47D (Figure 8B). In other words, 15d-PGJ2 
triggers increase in PPARγ activity in all three cell lines tested. Interestingly, this 
stimulation is especially obvious in cell lines that express high levels of PPARγ, 
which include MDA-MB231 and MCF7. More importantly, following this, a 
greater inhibition of NHE1 expression was also observed in MDA-MB231 and 
MCF-7, as compared to T47D, upon stimulation with PPARγ agonists, 15d-PGJ2 
determined by western blot and real time polymerase chain reaction (PCR). This 
observation suggests that both PPARγ activity and NHE1 gene expression could 
be controlled by employing basal PPARγ protein levels present in cells. Cells 
which have low level of PPARγ are minimally affected. This is clearly  seen  in 
T47D cell lines. This breast cancer cell line expresses lower level of PPARγ 
protein as compared to MCF7 and MDA-MB231. These results apprear to 
suggest that PPARγ agonists regulation of NHE1 is PPARγ-dependent .  
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In order to further confirm this hypothesis, using synthetic PPARγ ligands, the 
TZD group of drugs, rosiglitazone, troglitazone and ciglitazone, we wanted to 
know if the effect of synthetic PPARγ agonists on NHE1 expression  mimics 15d-
PGJ2. To our surprise, similar regulations were being observed (Figure 12D, E, 
F). These synthetic PPARγ agonists were shown to inhibit NHE1 expression 
differentially, probably due to the differences in binding affinity. Nevertheless, all 
these synthetic PPARγ agonists tested were shown to be able to regulate NHE1 
expression. Hence, we conclude that PPARγ agonists induced regulation of 
NHE1 expression is a PPARγ specific effect, and not a drug-specific effects.  
Next, assuming that PPARγ agonists regulation of NHE1 is truly limited by basal 
PPARγ expression in cells, we asked if this regulation is also plausible in normal 
cell lines. This is because PPARγ was previously shown to be highly expressed in 
breast cancer cells as compared to normal cells (Elstner et al., 1998). Hence, if 
our initial hypothesis is correct, PPARγ agonists regulation of NHE1 expression 
should not be observed in normal breast cells, which were shown to have PPARγ 
expression much lower than T47D. To confirm our hypothesis, MCF10 and 
HTB125 human normal breast cell lines were utilized. MCF10 cell line was 
derived from benign mastectomy tissue. These cells became spontaneously 
immortalized in culture into a non-tumorigenic, putatively normal cell line. 
HTB125 is another normal breast cells. It does not have estrogen receptor. 
Western blot analysis showed that both of these cell lines indeed have lower 
PPARγ expression as compared to breast cancer cell line, MCF7 (Figure 13A). 
These cell lines thus serve as excellent model for comparative investigation of 
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relevance of PPARγ expression in regulation of NHE1 expression. These two 
normal breast cell lines were firstly challenged with various doses of PPARγ 
agonist, 15d-PGJ2. Concentrations of 15d-PGJ2 (up to 5µM) that were previously 
shown to down regulate NHE1 expression in breast cancer cell lines were unable 
to elicit similar response in normal cell lines, both MCF10 and HTB125.   
Logical deduction subsequently led us to investigate if this could be due to low 
basal PPARγ expression in these cell lines. In order to demonstrate the 
importance of PPARγ expression in the regulation of NHE1, we overexpressed 
PPARγ in MCF10 and HTB125 normal breast cells. Interestingly, cells that 
overexpressed PPARγ we found to respond better to PPARγ agonists stimulation. 
There was an enhanced reduction in NHE1 expression upon treatment with 15d-
PGJ2 in cells that overexpressed PPARγ (Figure 14A, B). This was not being 
observed in cells that were transfected with control vector and thus did not 
express higher PPARγ protein level. Besides, we also ensured that the PPARγ 
that was overexpressed in cells was indeed active and responsive to 15d-PGJ2 
trigger. This was validated via PPRE luciferase assays (Figure 14C). There were 
enhanced PPARγ activities in cells that were transfected with PPARγ vector upon 
treatment with 15d-PGJ2, as compared to cells that were transfected with control 
vector.  
To further validate the results, both T47D and MCF7 cells were used to perform 
the same experiment. To our surprise, similar results were again being observed 
(Figure 15A, B). This serves as second line of evidence supporting  that PPARγ 
regulation of NHE1 expression is indeed a PPARγ dependent mechanism. 
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Increase in PPARγ expression in cells indeed leads to enhanced NHE1 reduction 
upon treatment with PPARγ agonists. Besides, using pharmacological PPARγ 
antagonist, GW9662, we showed that preincubation of cell with GW9662 prior to 
treatment with PPARγ agonists is able to block 15-PGJ2 induced PPARγ 
activation in MCF7, MDA-MB231 and T47D breast cancer cell lines (Figure 
16A, B, C). All these evidences simply strengthen our hypothesis that PPARγ 
agonists regulate NHE1 expression in breast cancer cell lines via a PPARγ-
dependent mechanism. 
Hence, data presented here support that repression of NHE1 gene expression by 
activation of PPARγ in tumor cells but not the adjacent normal cells could explain 
some of the effect of PPARγ ligand on tumor cells survival. Overexpression of 
PPARγ in tumor cells compared to normal cells and the induction tumor cell 
growth arrest upon exposure to PPARγ agonists have suggested that the use of 
specific PPARγ ligands as anticancer agents. The data presented here are an 
additional support for considering the treatment of cancer patient with PPARγ 
ligands as an efficient strategy to inhibit tumor cells growth and sensitize tumor 
cells to conventional chemotherapy. 
15d-PGJ2 and other cyclopentenone prostaglandins have been shown to induce 
ROS in diverse cell types, which could mediate their effects on cell death (Bureau 
et al., 2002; Lennon et al., 2002; Li et al., 2001). While we have identified 
PPARγ as a transcription factor for NHE1  gene regulation, we also demonstrated 
that PPARγ activation could be a source of reactive oxygen species (ROS) 
production. Cytometric analysis using H2DCF-loaded cells showed that 15d-PGJ2 
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increases intracellular steady-state ROS levels in all three breast cancer cell lines, 
namely MCF7, MDA-MB231 and T47D. Surprisingly, among the three cell lines 
used, MDA-MB231 produces the highest amount of ROS when challenged with 
PPARγ agonists, followed by MCF7 and T47D. This observation was surprising 
becauseMDA-MB231 cells also express higher level of PPARγ protein as 
compared to the other two cell lines (Figure 23A). Hence, it appears that there 
could be a correlation between the levels of ROS produced by 15d-PGJ2 to level 
of PPARγ protein expression in these cells.  
In order to explore  this probable correlation of PPARγ expression to ROS 
production, one way is to manipulate PPARγ expression in cells and to observe if 
changes in PPARγ expression leads to any change in ROS production when cells 
are challenged with 15d-PGJ2 . Accordingly, MCF7 cells were transfected with 
mouse PPARγ vector to induce overexpression of the protein. Surprisingly, 
PPARγ overexpression in MCF7 cells lead to more significant ROS production 
upon triggering with 15d-PGJ2 as compared to cells that were transfected with 
empty vector alone (Figure 23C). At 1 and 2 hrs after treatment with PPARγ 
agonists, MCF7 cells that overexpressed PPARγ produce significantly higher 
amount of ROS as compared to cells that were transfected with control vector. 
This observation inevitably suggests the involvement of PPARγ in PPARγ 
agonists induce ROS production in breast cancer cells! To further strengthen our 
finding, , using GW9662, a PPARγ antagonist, we show that ROS production by 
15d-PGJ2 in MCF7 cells can be prevented by PPARγ antagonist (Figure 23D). 
Combining these two observations, ROS production induced by PPARγ agonists 
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is thus very likely to be a PPARγ-dependent mechanism ROS production is 
downstream of PPARγ activation.. In addition, we also found that GW9662 by 
itself is able to produce ROS (Figure 23E). The mechanism by which GW9662 
itself produces ROS remains unclear. Apart from ROS production, we also 
observed striking changes in MCF7 cell morphology upon exposure to 15d-PGJ2. 
MCF7 cells were seen to rapidly detach from cell culture plates by 8 hours of 
treatment and ending with the majority of cells rounding up and floating in 
medium at 24 hours of treatment (especially at doses of 5µM). Treatment of these 
cells with propidium iodide staining assays then showed that polar dyes were able 
to be taken up by a large majority of the cells at about the same time that 
detachment from the culture dish was occurring, which could be indicative of 
necrosis (Figure 20A, C). However, cell cycle profile seems to suggest otherwise 
(Figure 21A). Hence, in this report, we present a novel cell death indicating that 
15d-PGJ2 induces cytotoxicity in MCF7 cells without a significant increase in 
apoptosis, or necrosis. It was observed that there is potent arrest of the cell cycle 
on G1 phase in MCF7 cells upon treatment with 15d-PGJ2 for 24hrs. Cells were 
arrested at this phase even up to 72 hrs (data not shown). The results presented 
here are in agreement with the data which suggests that 15d-PGJ2 is a potent 
cytoskeleton-disrupting agent, which may be the cause leading to cell cycle 
arrest.  
Moreover, pretreatment of MCF7 cells with ZVAD for 2hrs prior to treatment 
with 15d-PGJ2 was shown to be able to rescue cells from G1 arrest (Figure 21A). 
Interstingly, pretreatment with ZVAD was also able to block the early increase in 
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cell membrane permeability of MCF7 cells following treatment with 15d-PGJ2 
(Figure 20D). This suggests the involvement of caspases in the process. However, 
caspases involvement is very likely to be an early event in this system.  
Since MCF7 cells were observed to round up and detach from cell plates upon 
treatment of cells with PPARγ agonists from  8hrs onwards, we wanted to know 
the significance of cells undergong this process. Using crystal violet assays, we 
showed that there is indeed a decrease in viable cells upon treatment with 15d-
PGJ2 at 24hours and 48hours (Figure 20B). Since 15d-PGJ2 is a PPARγ agonist, 
we investigated whether the cytotoxic effects of 15d-PGJ2 on MCF7 cells were 
mediated by PPARγ activation. Hence, mouse PPARγ vector was again 
transfected into MCF7 cells for overexpression of the protein. The cells were then 
recovered and treated with 15d-PGJ2 for 24 hours, followed by assaying with 
crystal violet. Interestingly, it was observed that there is enhanced decrease in cell 
survival upon treatment with 15d-PGJ2 in cells that were transfected with mouse 
PPARγ vector as compared to cells that were transfected with empty vector alone 
(Figure 25A). In addition, we found that PPARγ was functional, because 
luciferase expression in MCF7 cells transfected with a PPRE-reporter construct 
increased after stimulation with 15d-PGJ2 in a dose-dependent manner. However, 
it is noteworthy that 15d-PGJ2 at different concentration can act differentially on 
the survival of MCF7 cells. This is because the enhancement seems to be true 
only at 3µM of 15d-PGJ2, but not at 5µM. This suggests that 15d-PGJ2 can 
activate multiple pathways involved in breast cancer cell survival and death. We 
therefore ask if ROS could be the underlying mechanism for death at high 
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concentration of 15d-PGJ2 as ROS was produced at the very early stage of 
induction. In this regard, 15d-PGJ2 and other cyclopentenone prostaglandins have 
been shown to induce ROS in diverse cell types, which could mediate their 
effects on cell death (Bureau et al., 2002; Lennon et al., 2002; Li et al., 2001). 
This prompted us to use ROS scavengers to determine if scavenging ROS 
prevents 15d-PGJ2-induced cell death. The presence of general ROS scavengers, 
NAC and DMTU showed differential effects. N-acetyl cysteine, a general 
antioxidant, was able to rescue cells from 15d-PGJ2 induced death while DMTU 
could not. DMTU scavenges hydrogen peroxide, and hydroxyl radicals whereas 
NAC reduces the overall oxidation state in the system partly by formation of 
glutathione. This suggests that probably ROS other than hydrogen peroxide, and 
hydroxyl radicals could be involved. These results are in agreement with those 
performed in human neuroblastoma SH-SY5Y cells and human hepatic 
fibroblasts showing that the increase in ROS production and cell death induced by 
15d-PGJ2 can be prevented by treatment with the antioxidant N-acetylcysteine (Li 
et al., 2001). To further confirm, cells were pretreated with tiron and catalase 
prior to treatment with 15d-PGJ2. Again, these two ROS scavengers were unable 
to rescue cells from dying. This data hence excluded the possibility of superoxide 
and hydrogen peroxide in being the ROS that was responsible for 15d-PGJ2 
induced cytotoxicity.  
Recently, there was a study which showed that PPARγ ligands 15d-PGJ2 and 
ciglitazone stimulate nitric oxide release from endothelial cells (Calnek et al., 
2003). Hence, we wondered if NO could be the ROS that leads to cell death in 
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our system. To investigate this, 5,10,15,20-Tetrakis(4-
sulfonatophenyl)prophyrinato iron (III), chloride (FeTPPS) was used. It is a 
porphyrin complex that catalytically isomerizes peroxynitrite to nitrate both in 
vivo and in vitro. FeTPPS  therefore provide cytoprotection against peroxynitrite 
(Misko et al., 1998). To our surprise, FeTPPS rescued MCF7 cells from 15d-PGJ2 
induced death. This strongly suggests the involvement of peroxynitrite in the 
death mechanism. Next, a nitric oxide (NO) scavenger was selected for our 
investigation. L-N
G
-Nitroarginine methyl ester (hydrochloride) (L-NAME) is a 
selective inhibitor for all three forms of nitric oxide synthase, hence inhibit nitric 
oxide production (Griffith and Kilbourn, 1996). MCF7 cells were preincubated 
with L-NAME prior to treatment with 15d-PGJ2 for 24 hours. Interestingly, 
crystal violet results showed that L-NAME could also rescue cells from 15d-PGJ2 
induced cytotoxicity. This also explains our earlier observation where NAC 
prevented 15d-PGJ2-induced cell death. It has been reported that antioxidant 
effects of NAC prevented the increase in
 
plasma peroxynitrite after ischemia 
(Conesa et al., 2001). 
Taken together, we showed that peroxynitrite is the ROS species responsible for 
the effects of 15d-PGJ2 observed. Peroxynitrite is a powerful oxidant species, 
which can be formed in vivo by the nonenzymatic reaction of nitric oxide (NO) 
and superoxide anion at an extremely rapid rate limited only by diffusion. 
Although convincing, further investigations need to be done in order to confirm 
NOS isoform involved and the role nitric oxide plays in this system. Regarding 
the source of superoxide anion production, they could be of mitochondrial or 
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extramitochondrial origin. It has been previously shown that 15d-PGJ2 is a potent 
inhibitor of mitochondrial complex I activity and a strong inducer of ROS 
production. It was also demonstrated that rotenone in MCF7 cells is a potent 
inhibitor of 15d-PGJ2-induced oxidative stress, which implicates complex I as the 
site of ROS production induced by 15d-PGJ2 (Martinez et al., 2005). From these 
published studies, one would postulate the source of superoxide production is 
probably mitochondrial when cells are challenged with 15d-PGJ2. However, more 
in depth investigations need to be performed   to confim the source superoxide 
and nitric oxide production in breast cancer cells when challenged with PPARγ 
agonists! This will be a very interesting and promising avenue to pursue in 
PPARγ biology as it is widely accepted now that enhanced peroxynitrite 
formation contributes to oxidative and nitrosative stress in a variety of 
cardiovascular and other pathologies (Denicola and Radi, 2005; Ferdinandy and 
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